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Adviser: Professor David A. Foster 
 
          Over the last decade, metabolic dysregulation in cancer cells has stimulated 
a significant amount of interest in basic research. It has been established that 
cancer cells increase glucose uptake and alter the fate of glycolytic and tricarboxylic 
acid (TCA) cycle intermediates for the synthesis of biological molecules to 
accommodate high rates of cellular growth and proliferation.  Moreover, it is more 
prominent that some metabolic dysregulations are specific to particular oncogenes. 
Exploiting the dysregulated metabolic dependency of cancer cells with therapeutic 
means could represent a novel approach for clinical aspect. 
          To meet the need of increased anabolic metabolism cancer cells engage in 
significant induction in uptake of glutamine, conditionally essential amino acid along 
with glucose. We investigated the impact of glutamine deprivation on cancer cell 
cycle progression and report here that K-Ras driven cancer cells override a 
glutamine mediated G1 cell cycle checkpoint and arrest in S-phase of cell cycle. 
Moreover this differential sensitivity to glutamine in K-Ras mutant cancer cells can 
be exploited using phase specific cytotoxic drugs. We also show that interfering 
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with anaplerotic utilization of glutamine sensitizes K-Ras driven cancer cells to the 
cytotoxic effects of cell cycle phase specific drugs. This study provides the rational 
for targeting metabolic deregulations in cancer cells. 
          Next we investigated the connection between the AMP activated protein 
kinase (AMPK) and phospholipase D (PLD). AMPK, cellular energy sensor, is 
dysregulated in most cancers whereas PLD is elevated in many cancers. PLD 
generated phosphatidic acid (PA) is a central metabolite of lipid biosynthesis and 
regulator of mTOR (mammalian/ mechanistic target of rapamycin) signaling node. 
Although negative impact of AMPK on mTOR has been reported previously little is 
known about the impact of mTOR on AMPK signaling. We have found that AMPK 
negatively regulates PLD activity in human cancer cells and in doing so it also 
suppresses the production of PLD generated PA, which positively regulates mTOR. 
We also show that PLD and PA suppresses AMPK in an mTOR dependent manner. 
This study suggests a negative feedback mechanism involving AMPK and 
PLD/mTOR signals in cancer cells. 
          To continue our study, we checked the effect of AMPK activator, AICAR (5-
Aminoimidazole-4-Carboxamide-1-β-4Ribofuranoside) combined with mTORC1 
inhibitor rapamycin on cell cycle progression. Rapamycin induces apoptosis in 
human cancer cells but in higher doses, which are not tolerable in the clinic. We 
report here that in presence of AICAR, rapamycin inhibits mTOR and induces 
apoptosis at clinically tolerable doses. We have demonstrated here that by 
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inhibiting PLD activity, AICAR suppresses the production of PLD generated PA, 
which interacts with mTOR in a competitive manner with rapamycin. The reduced 
level of PA sensitizes mTORC2 complexes to rapamycin in tolerable doses 
leading to suppressed Akt-dependent survival signals and causes apoptosis. This 
study provides the evidence that tolerable doses of rapamycin in combination with 
AICAR induces apoptosis in human cancer cells which could be a viable 








I take this opportunity to express my sincerest thanks and gratitude to my mentor, Dr. 
David A. Foster, for his excellent guidance throughout my graduate research. I joined his 
laboratory with no experience in cancer biology but he believed in me and he graciously 
accepted me as a graduate student. He kept faith on me and on my projects all the way. 
He taught me the importance of positive attitude for everything. His one-liners “What  does  
this  mean” and   “Say,  what   you  want   to   say”   I will never forget. He also trained me to 
become a good thinker rather a good lab technician. My experience in his lab was 
tremendous and allowed me to not only grow as a good scientist, but also a leader and 
mentor.  
I also extend my deepest gratitude to my committee members Dr. Derrick Brazill and Dr. 
Patricia Rockwell for providing me valuable suggestions and expert guidance. I am grateful 
for their patience which allowed me to develop clear understanding of my research. I am 
honored to have Dr. John Blenis and Dr. Ming Li to serve on my committee and grateful 
for their time and feedback on my work. I sincerely appreciate their expert opinions and 
valuable time for my work. 
I  don’t  believe  that  my  work could have been done without support of my lab mates. A big 
thanks to past and present lab members: Drs. Limei Xu, Paige Yellen, Mahesh Saqcena, 
Darin Salloum, Amrita Chatterjee and Deepak Menon, Deven Patel, Matthew Utter, Elyssa 
Bernfeld, Maria A. Frias, Limor Goren and Vishaldeep Vaghela. I was also lucky to have 
viii 
 
pleasure of working with two extraordinary undergraduate students, Carol Hosny and 
Diane Kogan, who contributed tremendously too many aspects of my work. 
I thank Inna Rakhlin and Brian Herbert for their support in teaching classes. My work could 
not have been done without any support from administrators of Biology Department. I want 
to thank all of my professors, teachers, and friends for their continuous support. 
 
Finally, I thank my family for their continuous support throughout my career. I am happy 
for this opportunity to publicly acknowledge my family. My mother, who is an amazing and 
inspiring person and has always had confidence on me and actively encouraged my 
diverse interests. My mother inspired my dream of being a scientist ever since I was a 
child. The words of gratitude to my father who has nurtured me with his love and care. 
Words alone cannot describe the gratitude I owe to my parents Sankar Kumar 
Mukhopadhyay and Piya Mukhopadhyay. I also thank my beloved wife, Shalini 
Mukhopadhyay for her support and help in all matters be it small or large. It would not have 
been possible to reach this stage without her encouragement. I am fortunate enough to 
have such a supportive and fascinating family members. I owe my family members 




                                                  Table of contents 
 
Title  page……………………………………………………………………………..          i 
Approval Page………………………………………………………………………..        ii 
Abstract………………………………………………………………………………..       iv 
Acknowledgements…………………………………………………………………..        vii 
Table  of  Contents…………………………………………………………………….       ix 
List  of  abbreviations…………………………………………………………………..      xii 
List of figures and Tables………………………………………………………...    xiii 
CHAPTER I ……………………………………………………………………..    1 
INTRODUCTION………………………………………………………………..    1 
1.1 METABOLIC REPROGRAMMING OF CANCER CELLS…………………………     2 
1.2 GLUTAMINE METABOLISM IN CANCER CELLS………………………………….    3 
1.3 MAMMALIAN TARGET OF RAPAMYCIN (mTOR)………………………………….    5 
1.3.1 OVERVIEW ON mTOR SIGNALING…………………………………………………..  5 
1.3.2 ACTION OF RAPAMYCIN ON mTOR SIGNALLING………………………………..   8 
1.3.3 DIFFERENTIAL SENSITIVITY OF mTOR TARGET P-S6K TO RAPAMYCIN……  9 
1.3.4 DIFFERENTIAL SENSITIVITY TO RAPAMYCIN BY DIFFERENT mTORC1  
Targets S6K1 AND 4E-BP1………………………………………………………………10 
1.3.5 DIFFERENTIAL INHIBITION OF mTORC1 AND mTORC2 BY RAPAMYCIN……..13 
1.3.6 ADVANTAGES OF RAPAMYCIN FOR THERAPEUTIC PURPOSES………………13 
1.4 PHOSPHOLIPASE D (PLD) AND PHOSPHATIDIC ACID (PA)……………………   14 
1.4.1 OVERVIEW OF PLD AND PA……………………………………………………………14 
1.4.2 ROLE  OF  PA  IN  mTOR  SIGNALING…………………………………………………....15 
1.5 AMPK………………………………………………………………………………………  18 
1.5.1 OVERVIEW OF AMPK…………………………………………………………………..   18 





METHODS AND MATERIALS………………………………………………………………21 




2.5 WESTERN BLOT ANALYSIS……………………………………………………………...24 
2.6 FLOW CYTOMETRIC ANALYSIS…………………………………………………………24 
2.7 CELL PROLIFERATION ASSAY……………………………………………………….....25 
2.8 TRYPAN BLUE EXCLUSION CELL VIABILITY ASSAY…………………………….....25 
2.9 PREPARATION OF PA…………………………………………………………………….25 
2.10 PLD ACTIVITY……………………………………………………………………………....26 
2.11 IMMUNOPRECIPITATION…………………………………………………………………26 
CHAPTER III………………………………………………………………………...27 
BLOCKING ANAPLEROTIC ENTRY OF GLUTAMINE TO TCA CYCLE 
SENSITIZES K-RAS MUTANT CANCER CELLS TO CYTOTOXIC  
DRUGS………………………………………………………………………………27 
3.1       INTRODUCTION…………………………………………………………………………...28 
3.1.1 PURPOSE OF THE STUDY IN THIS CHAPTER……………………………………….29 
3.2       RESULTS……………………………………………………………………………………29 
3.2.1 GLUTAMINE DEPRIVATION CAUSES S- AND G2/M-PHASE ARREST  
IN K-RAS MUTANT CANCER CELLS……………………………………………………29 
3.2.2 OVERRIDE OF Q-DEPENDENT G1 CHECKPOINT REQUIRES  
ACTIVATION OF MULTIPLE SIGNALINGPATHWAYS………………………………..34 
3.2.3 GLUTAMINE DEPRIVATION SENSITIZES K-RAS MUTANT CANCER CELLS  
TO PHASE SPECIFIC CYTOTOXIC DRUGS………………………………………......39 
3.2.4 PHARMACOLOGICAL INHIBITION OF Q ANAPLEROSIS SENSITIZES  
K-RAS MUTANT CANCER CELLS TO CYTOTOXIC DRUGS………………………..41 






RECIPROCAL REGULATION OF AMP-ACTIVATED PROTIEN KINASE  
AND PHOSPHOLIPASE D………………………………………………………52 
4.1 INTRODUCTION……………………………………………………………………………..53 
4.2 PURPOSE OF THE STUDY IN THIS CHAPTER…………………………….................54 
4.2 RESULTS……………………………………………………………………………………..54 
4.2.1 ACTIVATION OF AMPK SUPPRESSES PLD ACTIVITY……………………………54 
4.2.2 INHIBITING AMPK INCREASES PLD ACTIVITY IN A Rheb-DEPENDENT 
MANNER………………………………………………………………………………….58 
4.2.3 INHIBITION OF PLD ACTIVATES AMPK……………………………………………...60 
4.2.4 ACTIVATION OF AMPK BY PLD INHIBITION IS DUE TO REDUCED mTORC1 
           ACTIVITY………………………………………………………………………………….63 
4.3      DISCUSSION……………………………………………………………………………..66 
CHAPTER V………………………………………………………………………70 
AICAR ENHANCES THE EFFICIENCY OF RAPAMYCIN IN HUMAN  
CANCER  CELLS………………………………………………………………….70 
5.1       INTRODUCTION…………………………………………………………………………71 
5.1.1   PURPOSE OF THE STUDY IN THIS CHAPTER……………………………………73 
5.2       RESULTS………………………………………………………………………………...73 
5.2.1    AICAR TREATMENT CAUSES S-PHASE CELL CYCLE ARREST……………….73 
5.2.2    AICAR TREATMENT REDUCES THE CONCENTRATION OF RAPAMYCIN  
            TO INDUCE APOPTOSIS………………………………………………………………76 
5.2.3    APOPTOTIC EFFECTS OF AICAR AND RAPAMYCIN IS DEPENDENT  
            ON THE SUPPRESSION OF mTORC2 BY LOW DOSE RAPAMYCIN…………..78 
5.2.4    EFFECT OF AICAR ON RAPAMYCIN EFFICACY IS DUE TO SUPPRESION  
            OF PLD ACTIVITY……………………………………………………………………....83 




































List of abbreviations 
4E-BP1: eIF4E-binding protein 1 
ACC: acetyl-CoA carboxylase 
AICAR:  5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside 
AMPK: AMP-activated protein kinase 
eIF4E:  eukaryotic initiation factor 4E 
GAP: GTPase activating protein 
LKB1: liver kinase B1 
PA: phosphatidic acid 
mTOR: mammalian/mechanistic target of rapamycin 
PLD: phospholipase D 
Rheb: Ras homolog enriched in brain 
TSC: tuberous sclerosis complex 
ZMP: 5-aminoimidazole-4-carboxamide ribonucleoside monophosphate 
DMEM: Dulbecco’s  modified  Eagle  medium 
FK-BP12:  FK506-binding protein 12 
PBS:  phosphate buffered saline 
PCNA: proliferating cell nuclear antigen 
PARP: poly-ADP-ribose polymerase 
S6K: S6 kinase 
CDK: cyclin depedent kinase 
EAA: essential amino acids 
GF: growth factors 
R: restriction point 

















List of Figures  
 
Fig 1.1        SCHEMATIC OVERVIEW OF ANAPLEROTIC GLN UTILIZATION…………………4 
Fig 1.2         NUTRIENT SIGNALS TO MAMMALIAN TARGET OF RAPAMYCIN (mTOR)……..7  
Fig 1.3         MODEL FOR THE EFFECT OF PA ON mTORC1 and mTORC2……………………16 
Fig 1.4         SCHEMATIC REPRESENTATION FOR THE ROLE OF PA ON EFFICACY OF  
                    RAPAMYCIN……………………………………………………………………………….17 
Fig 1.5         PATHWAYS REGULATED BY ACTIVATED AMPK…………………………………..19 
Fig 1.6         THE LKB1/AMPK/mTOR SIGNALING PATHWAY…………………………………….20 
Fig 3.1         GLUTAMINE DEPRIVATION CAUSES S- AND G2/M-PHASE ARREST IN  
                    K-RAS MUTANT CANCER CELLS……………………………………………………..  31 
Fig 3.2         EFFECT OF GLUTAMINE DEPRIVATION ON PI3K/mTOR PATHWAY AND  
                    CELL CYCLE REGULATORY PROTIENS IN K-RAS WT AND MUTANT 
                    CANCER CELL LINES……………………………………………………………………33 
Fig 3.3         OVERRIDE OF Q-DEPENDENT G1 CHECKPOINT REQUIRES ACTIVATION 
                    OF MULTIPLE SIGNALING PATHWAYS………………………………………………36 
Fig 3.4         GLUTAMINE DEPRIVATION SENSITIZES K-RAS MUTATED CANCER CELLS 
                    TO PHASE-SPECIFIC CYTOTOXIC DRUGS…………………………………………40 
Fig 3.5         PHARMACOLOGICAL INHIBITION OF Q ANAPLEROSIS SENSITIZES K-RAS 
                    MUTANT CANCER CELLS TO CYTOTOXIC DRUGS……………………………….45 
Fig 3.6         SCHEMATIC OVERVIEW OF LATE G1 METABOLIC CELL CYCLE  
                    CHECKPOINTS……………………………………………………………………………50 
Fig 4.1         ACTIVATION OF AMPK SUPPRESSES PLD ACTIVITY…………………………….56 
Fig 4.2         INHIBITING AMPK INCREASES PLD ACTIVITY IN Rheb-DEPENDENT 
                    MANNER…………………………………………………………………………………...59 
Fig 4.3         INHIBITION OF PLD ACTIVATES AMPK………………………………………………61 
Fig 4.4         EFFECTS OF PLD ON AMPK ARE MEDIATED BY mTORC1………………………65 
Fig 4.5         MODEL FOR RECIPROCAL REGULATION OF AMPK AND PLD………………….67 
Fig 5.1         AICAR TREATMENT CAUSES S-PHASE CELL CYCLE ARREST…………………74 
Fig 5.2         AICAR TREATMENT REDUCES THE CONCENTRATION OF RAPAMYCIN 
                    TO INDUCE APOPTOSIS………………………………………………………………..77 
 
Fig 5.3         APOPTOTIC EFFECTS OF AICAR AND RAPAMYCIN IS DEPENDENT ON 
xv 
 
                    THE SUPPRESION OF mTORC2 BY LOW DOSE RAPAMYCIN……………….. 81 
 
Fig 5.4         EFFECT OF AICAR ON RAPAMYCIN EFFICACY IS DUE TO SUPPRESION  
                    OF PLD ACTIVITY………………………………………………………………………84 
Fig 5.5         MODEL…………………………………………………………………………………...86 
 
                      
 














1.1   Metabolic reprogramming of cancer cells 
          The complexity of the cancer has been linked to six basic alterations of cell 
physiology which together creates malignant cell growth (1). Among them two are related 
to yielding a phenotype of sustained uncontrolled cell proliferation and escaping from cell 
death. Mutations in oncogenes and tumor suppressors along with other factors also been 
shown to influence the malignant cell growth (1). Cancer cells also undergo metabolic 
reprogramming, which is one of the  emerging hallmarks in cancer (1). Under aerobic 
conditions cancer cells reprogram their glucose metabolism and depend more on “aerobic 
glycolysis” for their energy production (2). A sustained glycolysis has been linked to 
enhanced cell proliferation and tumor aggression in vivo (3). Cancer cells undergo 
significant metabolic reprogramming, which helps to sustain continuous growth and 
proliferation (4,5). However there is speculation on the involvement of specific oncogenic 
pathways on this metabolic switch of cancer cells. Altered metabolic rewiring makes 
cancer cells more proficient for uncontrolled cell growth. Deregulation of several signaling 
pathways in tumors leads to metabolic alterations in cancer cells (6). Cancer cells evade 
growth factor dependence by gaining genetic mutations which functionally reprogram 
signaling pathways to lead uncontrolled cell proliferation. Evidence from recent research 
suggests that metabolic reprogramming of signaling pathways lead to constitutively 
activate uptake and metabolism of nutrients, which generates survivals signals and 
promotes cell growth (2). Recent findings also suggest that several differences are 
present in cancer cells compared to their normal counterparts. Since metabolism is one 
of the precursors for cellular growth, better understanding of cancer cell metabolism is 
required for targeting cancer cells specifically. Differences in metabolism in cancer cells 
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compared with non-cancer cells would be targets for clinical intervention. Clear 
understanding of altered metabolism in cancer cells will help to create  new targets for 
therapeutic interventions.  
1.2   Glutamine metabolism in cancer cells 
          Over the last decade, there has been a resurgence of interest in metabolism 
stimulated largely by the observation that there is a metabolic reprogramming of cancer 
cells (7).  To meet the increased anabolic demand to accommodate cell growth and 
proliferation, cancer cells elevate glucose uptake and reprogram the fate of glycolytic and 
tri-carboxylic acid (TCA) cycle intermediates towards synthesis of amino acids, 
nucleotides, and lipids needed for the cell to double its mass and divide.  In dividing cells, 
citric acid, which is synthesized from the condensation reaction between acetyl-CoA and 
oxaloacetate in the first step of the TCA cycle, exits the mitochondria and regenerates 
acetyl-CoA, which is then used for the generation of lipids needed for membrane 
biosynthesis.  The exit of citric acid from the mitochondria and the TCA cycle creates a 
need for anaplerotic replenishment of TCA cycle intermediates downstream of citric acid.  
The major source for anaplerotic replenishment of TCA cycle intermediates is the 
“conditionally  essential”  amino  acid  glutamine  (Gln).     It has been shown that Gln is an 
actively metabolized substrate for cancer cells (8). Although it has been reported that 
glucose deprivation causes cell death in several cancer cells whereas Gln deprivation 
arrests cell proliferation (3,9) it is not yet completely clear how glutamine is required for 
to support uncontrolled cancer cell growth.  
     Gln is most abundant amino acid in human plasma and is involved in several metabolic 
pathways. Cancer cells consume more Gln compared to their normal counterparts in 
4 
 
higher rates (4). After being transported into mitochondria Gln is first deaminated to 
glutamate, and then to -ketoglutarate via either glutamate dehydrogenase or 
transamination reactions with -keto-acids such as oxaloacetate to generate aspartate 
(Figure 1.1).  As much as 25% of Gln gets incorporated into membrane lipids (8) – 
indicating that a substantial amount of Gln is converted to citric acid for export to the 
cytosol for fatty acid synthesis.  Gln-derived -ketoglutarate is also critical for redox 
balance and the generation of NADPH via the conversion of malate to pyruvate (Figure 
1).  These observations underscore the critical importance of Gln as a nutrient source in 
dividing and metabolically reprogrammed cancer cells. 
 
Figure 1.1.  Schematic overview of anaplerotic Gln utilization. Adapted 
from(10):  Gln is first deaminated to glutamate by glutaminase (GLS).  Glutamate is 
then converted to -ketoglutarate via either glutamate dehydrogenase (GDH) or 
transamination catalyzed by glutamate oxaloacetate transaminase (GOT), which 
uses oxaloacetate as the amino group acceptor to generate aspartate.  
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Aminooxyacetate (AOA) inhibits GOT and therefore suppresses generation of 
-ketoglutarate from Gln-derived glutamate.  Aspartate is critical for redox balance 
and NAPDH production (11) and the generation of citrate for fatty acid synthesis.  
Gln is also important for redox balance via the conversion of malate to pyruvate, 
which also generates NADPH.  
          Consistent with the importance of Gln as a nutrient for dividing cells, we recently 
identified a late G1 Gln-dependent cell cycle checkpoint that could be distinguished from 
two other late G1 checkpoints – one that was dependent on essential amino acids, and 
another that is dependent on mTOR(12).  All three metabolic checkpoints were clearly 
distinguished from the mid-G1 growth factor-dependent Restriction Point (12).  
1.3   Mammalian Target of Rapamycin (mTOR) 
1.3.1. Overview on mTOR signaling 
          mTOR, the mechanistic/ mammalian target of rapamycin, is a serine/threonine 
protein kinase that regulates cell metabolism, growth, proliferation and survival in 
response to environmental signals provided by growth factors, nutrients, oxygen, energy 
and stress (13). mTOR acts as the catalytic subunit in two large multiprotein complexes: 
mTORC1 and mTORC2. The binding partner Raptor defines mTORC1 (14,15), whereas 
Rictor defines mTORC2 (16,17). Both complexes contain several other structural and 
regulatory components required for their function (18-23) . mTORC1 phosphorylates 
several downstream targets to promote biosynthesis of proteins, lipids and nucleotides, 
while turning off autophagy, which is a major macromolecule degradation mechanism 
(24). S6K and 4E-BP are by far the best characterized mTORC1 targets, since they were 
the first to be discovered several decades ago (25,26). S6K phosphorylation on threonine 
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389 (Thr389) (27) leads to ribosome biogenesis. Sequential phosphorylation of 4E-BP at 
the residues threonine 37/46 (Thr37/46), serine 65 (Ser65) and threonine 70 (Thr70) 
prevents binding and sequestration of the eukaryotic translation initiation factor eIF4e, 
which drives CAP-dependent translation initiation (28,29). Much less is known about 
mTORC2 relative to mTORC1 (30). However, this complex plays seminal functions in cell 
metabolism and survival through the phosphorylation of serine 473 (Ser473) of AKT, one 
of the main cellular proto-oncogenes(31). The general overview of mTOR signaling is in 
fig 1.2.  
Mutations in tumor suppressors and/or oncogenes upstream of mTORC1 result in 
increased activation of mTORC1, making such cancer cells distinct from their normal 
counterparts and especially vulnerable to mTORC1 inhibition (32). Altered cell 
metabolism, uncontrolled proliferation and enhanced survival through the loss of 
apoptotic programing are major hallmarks of cancer (1). Since mTORC1 is a key regulator 
of such cellular functions it is not surprising that mTORC1 hyper-activation has been 
found in most human cancers (33). This opens the possibility of selectively targeting 
cancer cells through inhibition of mTORC1. As its name implies, mTOR is the target of 
rapamycin, a macrolide antibiotic with critical anti-proliferative properties. Much of what is 
currently known about mTOR came from studies trying to understand the mode of action 
of rapamycin (34). Rapamycin first binds to its intracellular receptor, FKBP12, and then 
binds to and inhibits mTOR (35). Rapamycin does not directly inhibit the mTOR kinase. 
Instead, it works as an allosteric inhibitor through binding to the FRB (FKBP12-
Rapamycin binding) domain of mTOR (amino acid residues 2025 to 2114), which is 
located immediately N-terminal to the kinase domain (36). Binding of rapamycin causes 
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conformational changes in mTOR (37) that affect complex assembly (38) and substrate 
binding (39) mTORC1 is sensitive to rapamycin while mTORC2 is less sensitive to the 
drug. Within one hour, rapamycin disrupts the association between mTOR and raptor but 
not with rictor (40). Raptor plays a key role in mTORC1 substrate recognition and thus 
rapamycin also affects substrate binding (41). However, 24hr or longer exposures to 
rapamycin also inhibit mTORC2 (42). Unassembled mTOR bound to rapamycin fails to 
assemble into mTORC2 and turn over the active complex. Thus mTORC2 activity is lost 
over time. 
 
Figure 1.2. Nutrient signals to mammalian target of rapamycin (mTOR) Adopted 
from (43): Regulation of mTOR has many inputs. The phosphatidylinositol-3-kinase (PI3K) 
input involves the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to PIP3, 
which recruits and activation (PDK1), which in turn phosphorylates Akt at Thr308. 
Subsequently, Akt phosphorylates and suppresses the GTPase-activating protein 
(GAP) activity of the tuberous sclerosis complex (TSC) consisting of TSC1 and 
TSC2 (TSC1/2). Suppression of TSC1/2 activates the GTPase Rheb, which than 
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activates mTORC1 via the activation of phospholipase D1 (PLD1) and suppression 
of FKBP38 whereby elevated PLD activity generates the phosphatidic acid (PA) 
necessary for the formation of the mTORC1 complex and the dissociation of 
FKBP38 from mTORC1. This pathway is also modulated by AMP-activated protein 
kinase (AMPK) which, in combination with the tumor-suppressor LKB1, activates 
TSC1/2, which then suppresses Rheb and thus mTOR – under conditions where 
ATP levels are low and AMP levels are high. Akt is also phosphorylated by mTORC2 
at Ser473 in response to insulin and insulin-like growth factor-1 (IGF1) in a PLD-
dependent manner. Phosphorylation at this site has been correlated with altered 
substrate specificity and kinase activity for Akt. Insulin also increases the level of 
glucose transporters and the uptake of glucose. A common theme in this complex 
signaling network leading to mTORC1 activation is that it is highly sensitive to the 
presence of glucose and amino acids – nutrients needed for cell growth. 
 
1.3.2. Action of Rapamycin on mTOR signaling 
          Rapamycin derivatives known collectively as rapalogs are presently FDA-approved 
drugs for the treatment of certain cancers (44) . Results of clinical trials have not met the 
high expectations for rapamycin in cancer therapy. Intrinsic and acquired resistance to 
rapamycin have been widely observed both in pre-clinical and clinical studies (34). mTOR 
inhibition through rapamycin has traditionally been measured through the levels of 
phosphorylation of Thr389-S6K1 and cell proliferation/viability assays. It has long been 
known that the tolerated dose of rapamycin, at a low nanomolar range, does not inhibit 
P-Thr389-S6K1 equally between different cancer cell types (45,46). Some require higher 
doses of rapamycin. In recent years it has also become evident that the low nanomolar 
doses of rapamycin required for P-Thr389-S6K1 inhibition are not enough to target 
phosphorylated 4E-BP1 (47) (48,49). Higher doses of rapamycin are required for 
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complete inhibition of 4E-BP1(50). Moreover, inhibition of mTORC2 with prolonged 
nanomolar doses will not happen in some cancer cell types(42), which might require 
higher doses of rapamycin for inhibition of P-Ser473-Akt.  
 
1.3.3. Differential sensitivity of mTORC1 target P-S6K to 
rapamycin 
          Initial evidence that different cancer cells respond differently to rapamycin came 
from studies with rapamycin or rapalogs with cultured cancer cell lines. More recent 
studies with mouse tumor xenografts and cancer samples have led to identical 
conclusions (34). Some cancer cells show extreme sensitivity to inhibition of P-S6K1 with 
rapamycin, with IC50s between 0.5 and 10 nM. Other cells show good sensitivity to 
rapamycin with IC50s around 100nM. Overall, cancer cells with increased activation of 
the PI3K growth factor pathway tend to be sensitive to rapamycin in low nanomolar doses 
(1-100 nM). These cells have high basal levels of P-Thr389-S6K1 and P-Ser473-Akt and 
these have been found to be good predictors of rapamycin sensitivity by several 
independent studies (51). These cells are resistant to rapamycin and they have been the 
subject of many studies trying to underscore the mechanisms of resistance to rapamycin. 
Several factors have been associated with intrinsic resistance to rapamycin. The list is 
long and includes mutations in mTOR and FKBP12, mutations in proteins associated with 
DNA damage responses, reduced levels of 4E-BP or negative regulators of the cell cycle, 
among others(52) .Importantly, recent studies have shown that there is a positive 
correlation between PLD activity and the dose of rapamycin required for P-S6K1 inhibition 
(53,54).Our lab and others have shown that PLD-generated PA is required for mTOR 
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activity in response to nutrients (55-58) and that PA interacts with the FRB domain of 
mTOR in a competitive way with rapamycin (54,59). In breast cancer cells, cell growth 
inhibition can be achieved at 20 nM concentration of rapamycin for MCF-7 cells whereas 
20 µM is required for MDA-MB-231 cells (53) . Regarding P-S6K, 0.5 nM rapamycin are 
enough to suppress phospho-Thr389-S6K in MCF7 cells whereas 20 nM is required in 
MDA-MB-231 cells. The latter have a 10-fold increase in PLD activity relative to MCF-7 
cells. MDA-MB-231 cells produce more PA and therefore require higher amounts of 
rapamycin to compete off PA and inhibit mTOR. Critically, elevation of PLD activity by 3 
fold in MCF-7 cells leads to a 10-fold increase in the dose of rapamycin required to inhibit 
P-Thr389-S6K1. Similarly, a 3-fold reduction of PLD activity in MDA-MB-231 cells 
sensitizes these cells to rapamycin by lowering the dose required for S6K1 inhibition from 
50nM to 5 nM (10 fold) (53). These findings give PLD-generated PA a key role in mTOR 
activation in a manner that is competitive with rapamycin.  Importantly, they open the 
possibility of mTOR inhibition in rapamycin resistant cells through combined therapy with 
PLD inhibitors. 
 
1.3.4. Differential sensitivity to rapamycin by different mTORC1 
targets - S6K1 and 4E-BP1 
          Historically, mTOR inhibition has been probed through the levels of P-Thr389-
S6K1. There is a fundamental reason for that: researchers did not feel comfortable with 
results achieved with 4E-BP1. Several factors were responsible for this uncertainty. 4E-
BP1 has 4 mTOR-dependent sites that show different levels of inhibition at the nanomolar 
range doses. In addition, mammals have three 4E-BP genes and proteins and therefore 
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there might be antibody cross-reactivity with the same sites in 4E-BP2 and 4E-BP3. Data 
generated for phospho-4E-BP1 was difficult to interpret and therefore was frequently 
excluded. It is now widely accepted that low nanomolar doses of rapamycin often lead to 
complete inhibition of S6K but only partial inhibition of 4E-BP1. Two lines of research, 
one with mTOR catalytic inhibitors (47-49) and one with high dose rapamycin (50), helped 
establish the idea of partial inhibition of 4E-BP1 by low dose rapamycin. The development 
of ATP-competitive kinase inhibitors of mTOR by several independent groups (47-49) 
showed that these compounds induced a more profound inhibition of mTORC1. They lead 
to complete suppression of phospho-4E-BP1, which translated into a deep cell cycle 
arrest and inhibition of proliferation. Since the catalytic inhibitors of mTOR affect both 
mTORC1 and mTORC2, there was concern that inhibition of mTORC2 contributed to the 
profound proliferation inhibition. However, identical proliferation inhibition kinetics 
achieved in WT and rictor -/- (47) or Sin1-/- (48) MEFS showed that it was indeed due to 
complete inhibition of phospho-4E-BP1. Importantly, studies using micromolar 
concentrations - high dose - rapamycin lead to the same conclusions. Data from Yellen 
et al., 2011 (50) suggests that low dose rapamycin induces a weak dissociation between 
mTOR and raptor since the presence of a protein cross-linker can recover the interaction. 
This is enough to prevent S6K phosphorylation but not 4E-BP1 phosphorylation. 
Significantly, at micromolar doses, rapamycin causes a strong if not complete dissociation 
between mTOR and raptor, which can no longer be recovered by protein crosslinking. In 
these conditions there is complete suppression of phospho-4E-BP1. Blenis and 
colleagues have suggested that S6K interacts with Raptor more weakly that with 4E-BP1 
(39,41). This supports the idea that low doses of rapamycin have a weak effect on Raptor 
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but which are enough to prevent binding of S6K, whereas 4E-BP1 requires a more 
profound destabilization of mTORC1 to prevent its binding to Raptor. A very important 
aspect of the study of Yellen et al., (50) is that complete inhibition of phospho-4E-BP1 
lead to a complete cell cycle arrest and apoptotic cell death in certain cell growth 
conditions. Apoptosis was due to complete suppression of eIF4E by 4E-BP1 since it could 
be reproduced by knocking down eIF4E and it could be rescued by knocking down 4E-
BP1. This also cleared any concerns regarding the specificity of high dose rapamycin by 
showing a specific effect on 4E-BP1. The fact that high dose rapamycin can kill cancer 
cells suggests that complete inhibition of mTORC1, in certain conditions, can be cytotoxic 
instead of cytostatic, which would have profound implications in cancer therapy. 
Additionally, these results might explain the reason why for so many decades researches 
tried to use rapamycin to cause cancer cell death without much success: nanomolar 
doses of rapamycin lead to partial inhibition of 4E-BP1 only. Data from the clinic support 
a critical role for 4E-BP1 in cancer development. An increase in 4E-BP1 phosphorylation 
status reduces overall survival of metastatic melanoma patients (60). High dose 
rapamycin can lead to apoptosis, but it cannot be tolerated by cancer patients. Therefore 
finding a way to achieve complete mTORC1 inhibition at the well tolerated nanomolar 
doses of rapamycin is a major concern. This could potentially be achieved through the 
combination of low dose rapamycin with other drugs with an inhibitory effect on mTORC1 





1.3.5. Differential inhibition of mTORC1 and mTORC2 by 
rapamycin 
          The existence of feedback loops downstream of mTORC1 that impact on cell 
survival pathways can impose limits to the efficacy of rapamycin-based treatments. In 
response to suppression of S6K phosphorylation, induction of Akt phosphorylation has 
been reported in some cancer cells (61). Thus mTORC1 inhibition by rapamycin results 
in feedback activation of mTORC2 and phosphorylation of the survival kinase AKT. This 
negative feedback loop was responsible for saving cells from apoptosis induced by high 
dose rapamycin in breast cancer (50) and pancreatic cancer cells (62). Importantly, 
inhibition of mTORC2 or suppression of AKT phosphorylation restored the apoptotic effect 
of high dose rapamycin. These results suggest that the treatment of cancer cells that 
display the negative feedback loop between S6K and AKT might require inhibition of both 
mTORC1 and mTORC2. mTORC2 is resistant to rapamycin in both low and high dose. 
Regardless of dose, prolonged treatment with rapamycin can lead to suppression of 
mTORC2 in some cancer cells (42). This suggests that mTORC2 has a long half-life and 
that over time rapamycin prevents free mTOR bound to rapamycin from assembling into 
new mTORC2.  
 
1.3.6. Advantages of rapamycin for therapeutic purposes 
Rapamycin is an allosteric inhibitor of mTOR that has been widely used in both 
pre-clinical and clinical settings. A second generation of mTOR inhibitors has more 
recently been developed. These are ATP-competitive inhibitors that disable the kinase 
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activity of mTOR. These compounds present two major advantages relative to rapamycin: 
they present greater efficacy in mTOR inhibition and they inhibit both mTORC1 and 
mTORC2. However, like other ATP-competitive inhibitors, these compounds seem to be 
associated with greater toxicity and lower specificity. Another pitfall of the mTOR catalytic 
inhibitors comes from shorter durations of activity. In contrast, rapamycin is a natural 
product that allosterically inhibits mTOR with a very high specificity. Even high doses of 
rapamycin do not seem to produce off-target effects. However, high doses of rapamycin 
cannot be administered in the clinic and this might be the main reason why nanomolar 
doses of rapamycin have not lead to more impressive results in clinical trials.  
In order to take advantage of low toxicity and high specificity of rapamycin for mTOR, 
there need to be a means for making rapamycin more efficient at lower doses. One 
possible strategy is to introduce rapamycin through a vehicle. For example, tagging 
rapamycin to glucose, which is taken up preferentially by most cancer cells. Such a 
method could help deliver tolerable levels of rapamycin and cause greater toxicity in the 
tumor microenvironment. 
 
1.4   Phospholipase D (PLD) and Phosphatidic Acid (PA) 
1.4.1 Overview of PLD and PA 
          Phospholipase D is an enzyme that catalyzes the hydrolysis of phosphatidylcholine 
into phosphatidic acid (PA) and choline. PLD is evolutionary conserved lipase from 
bacteria to mammals. Two isoforms of PLD (PLD1 and PLD2) are exist in mammals 
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among them PLD1 is more responsive to growth factors and nutritional stimuli (55,57,63). 
PLD1 is localized to perinuclear regions of the cell with a pattern 
consistent with that of the Golgi apparatus, endoplasmic reticulum and endosomes (64). 
It has been reported that PLD1 also localized in the plasma membrane after stimulated 
by phorbol 12-myristate-13-acetate (PMA), insulin (65,66). On the other hand, most 
reports demonstrate that PLD2 localizes to the plasma membrane (67), but it has been 
found in the cytosol, vesicular compartments (68). 
PLD has been implicated in a number of cellular activities, including cell migration, 
exocytosis and receptor endocytosis(63,69). These functions are vital for the cell survival 
but are also common contributors to tumorigenesis. Not surprisingly, PLD, whose activity 
is elevated in a large number of human cancers, has been implicated in the survival 
signals that suppress apoptosis when the cells are subjected to stress of serum 
withdrawal (70,71).  Mammalian PLD proteins are highly responsive to growth factor and 
hormone stimulation. Numerous reports provide evidence which show that PLD activity 
can be stimulated by epidermal growth factor (EGF), platelet derived growth factor 
(PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and 
insulin in various systems. In some of these cases, PLD proteins have been shown to 
physically associate with the receptors of the aforementioned growth factors. Inhibitors of 
tyrosine kinases such as genistein inhibited PLD activity stimulated by various agonists. 
On the other hand, inhibition of protein tyrosine phosphatases with compounds such as 
vanadate, stimulated PLD activity (72).  
PA can function as a second messenger to activate various kinases including mTOR. In 
addition, PA is an essential substrate for enzymes involved in the synthesis of 
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glycerophospholipids and triacylglycerols. PA stands in the center of lipid synthesis, both 
for membrane phospholipids and triglyceride synthesis (43,73). 
 
1.4.2 Role of PA in mTOR signaling 
          PA is a phospholipid that binds to the FRB domain of mTOR (59) to promote 
complex assembly and stability (54). Detailed study on how the levels of cellular PA and 
the levels of activity of its generating enzyme, phospholipase D, can explain required 
higher doses of rapamycin to achieve full inhibition of mTOR by some cancer cell types. 
     Recent findings have shown that strong reductions in intracellular levels of PA lead 
not only to mTORC1 inactivation but also mTORC2 inactivation (54). These findings 
support the idea that the affinity of PA for mTORC2 is greater than for mTORC1. PA 
allows a greater stability to mTORC2 compared to mTORC1. Critically, PA binds to mTOR 
in a competitive manner with rapamycin thus the differential sensitivity of mTORC1 and 
mTORC2 to rapamycin can be explained by the differential affinity of mTORC1 and 
mTORC2 to PA (Figure 1.3). The higher sensitivity of mTORC1 to rapamycin is consistent 
with the lower affinity of PA for mTORC1. Similarly, a higher affinity of PA to mTORC2 is 
coherent with lower sensitivity to rapamycin. In other words, PA easily dissociates from 
mTORC1 in the presence of rapamycin but not from mTORC2. The dissociation constant 
for PA and mTORC2 is therefore much lower than the dissociation constant for PA and 
mTORC1 (Figure 1.3). A PA-centered model for the differential sensitivity of mTORC1 
and mTORC2 to rapamycin, though oversimplified, opens the possibility of new routes of 
cancer therapy with drugs that significantly lower the levels of PA in combination with 




Fig 1.3. Model for the effects of PA on mTORC1 and mTORC2: The rate constant 
for the dissociation of mTORC1 to PA and mTOR (KD1) is greater than rate 
constant for the dissociation of mTORC2 to PA and mTOR (KD2).There are less 
disassociations of PA from mTORC2 compare to mTORC1.The efficient ability of 
rapamycin-FKBP12 to suppress mTORC1 and mTORC2 depends on the 
availability of mTOR availability to bind with rapamycin-FKBP12. Reduction of PA 
by PLD inhibitors would reduce the concentration of rapamycin-FKBP12 needed 
to bind to and inhibit mTOR. 
Our lab has demonstrated that inhibition of PLD activity leads to lower intracellular 
levels of PA, which in turn allow rapamycin to inhibit both mTORC1 and mTORC2 at lower 
doses. PLD inhibitors (74) have been developed by the group of Alex Brown and are 
presently undergoing clinical trials (75) for certain human disorders and have also been 
reported safe and efficient. The combination of PLD inhibitors with low dose rapamycin 
has great potential as an anti-cancer therapy and deserves further research to establish 
major beneficial properties and pitfalls. The schematic representation of this strategy is 
been proposed in Fig 1.4. Suppressing PLD activity by PLD inhibitors – makes mTORC2 
sensitive to rapamycin at clinically tolerated doses.  Thus, while the combination of PLD 
inhibitors and rapamycin might seem redundant – they both suppress mTORC1, and as 
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a consequence, make mTORC2 responsive to tolerated doses of rapamycin leads to 
suppression of mTORC2 as well as mTORC1.  
 
 
Fig 1.4: Schematic representation for the role of PA on efficacy of rapamycin:  
Low doses of rapamycin treatment inhibit S6K phosphorylation very efficiently but 
fail to inhibit 4E-BP1 phosphorylation whereas high doses of rapamycin treatment 
efficiently inhibit both of them but in clinically non tolerable doses. It is arguable 
that combination of PLD inhibitors and low dose rapamycin treatment would inhibit 
mTORC1 efficiently. Additionally this duel treatment would inhibit the survival 
signal generated from mTORC2, which would result in synthetic lethal phenotype 




1.5.1 Overview of AMPK 
          AMPK is a serine-threonine  kinase  which  acts  as  a  ‘energy  sensor’  that  responds  
to the changes in cellular metabolic ATP levels(76). Once cellular ATP levels goes down 
by various stressful conditions such as oxygen deprivation and heat shock, AMPK gets 
activated and functions by inhibiting energy consuming process while activating ATP-
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producing pathways. Thus AMPK works to optimize the total cellular ATP levels in order 
to maintain critical physiological processes or for survival in response to stress (76,77). 
The  heterotrimeric  AMPK  contains  a  catalytic  α-subunit  and  regulatory  β  and  γ  subunits.  
The  α-subunit contains critical feature for enzymatic activity, the N-terminal kinase domain 
contains a threonine residue (Thr-172) whose phosphorylation is essential for AMPK 
activation (76). Mammalian AMPK is activated by 5’-AMP (AMP), whereas it is inactive 
unless phosphorylated on its threonine residue (Thr-172) by upstream kinases (78,79). 
Phosphorylation of AMPK at Thr172 is critical for enzymatic activity and upstream kinase 
LKB1 is responsible for this phosphorylation. LKB1 activates AMPK through 
phosphorylation of Thr172 and is essential for activation of AMPK by exercise (80)or 
widely used drug for diabetes metformin(81). Mammalian cells lacking LKB1 expression, 
cannot activate AMPK upon treatment of anti-diabetic drugs phenformin or 5-





Fig 1.5: Pathways regulated by activated AMPK (Adopted from (77): AMPK 
suppresses the activity of various proteins involved in anabolic pathways (top half 
of wheel) whereas catabolic pathways are switched on by AMPK.  
 
1.5.2 AMPK signaling network 
          AMPK acts as an energy sensor of the metabolic state of the cell. AMPK regulates 
several metabolic pathways as it acts like metabolic switch of the cellular metabolism. 
Upon activation AMPK leads to energy preservation for cell survival, inhibits all ATP 
consuming pathways while it also activates ATP generating signaling pathways for 
cellular survival. Pathways regulated by activated AMPK is illustrated in figs 1.5, 1.6. After 
activation, AMPK controls multiple targets including mTOR signaling and lipid biogenesis 
pathways. AMPK plays a major role in regulating cell growth, proliferation and autophagy 
through inhibiting mTOR signaling cascade(79). AMPK inhibits a number of key 
metabolite enzymes that consume ATP but are not immediate essential for survival. 
These proteins include acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), HMG-
CoA reductase, mTOR (77). AICAR is one of the activator of AMPK most widely used in 
the cell culture studies. AICAR is a precursor of zinc metalloproteinase (ZMP), which 
competes  with  AMP  for  binding  to  AMPKγ  subunit.  Activated  AMPK  by  AICAR  treatment  
inhibits amino acid induced activation of p70S6K (83). AMPK phosphorylates and 
activates tumor suppressor TSC2 which subsequently inhibits mTOR. AMPK also 
phosphorylates mTORC1 partner raptor and inhibits the mTORC1 complex (84).  





                
Fig 1.6: The LKB1/AMPK/mTOR signaling pathway (Modified from (79): Activated 
AMPK upon treatment of AICAR critically inhibits two majot anabolic pathways. 
AMPK phosphorylates and activates TSC2, negative regulator of mTOR pathway. 
By inhibiting mTOR, AMPK negatively regulates protein translation process 
whereas AMPK also negatively regulates lipid biogenesis by inhibiting acetyl CoA 























2.1 Cells, cell culture conditions 
The Calu-1, DU-145, LNCaP, MCF-7, MDA-MB-231, Panc-1 and BJ-hTERT cells used in 
this study were obtained from the American Tissue Type Culture Collection.  LNCaP cells 
were maintained in RPMI-1640 and all the other cells were maintained in DMEM 
supplemented with 10% fetal bovine serum (Sigma) and penicillin/streptomycin (Sigma). 
Transfections were performed using Polyfect (Qiagen) for plasmid transfection and 
Lipofectamine  RNAiMAX  (Invitrogen)  for  siRNA  transfection  according  to  manufacturer’s  
instructions. 
2.2 Materials 
Reagents were obtained from the following sources: Antibodies against phospho-Akt 
(T308 and S473), phospho-S6K (T389), phospho-4EBP1 (T37/46), phospho-ERK1/2 
(T202/Y204), phospho-Rb (S807/811), cyclin E, cleaved PARP, and actin were obtained 
from Cell Signaling; antibody against p27 was obtained from Santa Cruz Biotechnology; 
antibodies against cyclin A, cyclin B, and cyclin D were obtained from BD Biosciences; 
and anti-mouse and anti-rabbit HRP conjugated secondary antibodies were obtained from 
Promega.  DMEM (D6429), DMEM lacking Gln (D5546), RPMI-1640 (R8758), RPMI-1640 
lacking Gln (R0883), dialyzed fetal bovine serum (F0392), and glutamine (G7513), 
aminooxyacetic acid hemihydrochloride (AOA) (C13408), were obtained from Sigma.  
U0126 (9903) was obtained from Cell Signaling, Torin1 (4247) was obtained from Tocris.  
Paclitaxel (P-9600) and Capecitabine (C-2799) were obtained from LC Laboratories. 
Antibodies against P-AMPK (Thr172), AMPK, HA-Tag, ACC, phospho-ACC (Ser79), 
LKB1, Rheb, TSC2, phospho-TSC2 (Ser1387), mTOR, Raptor , ULK1, phosphor-ULK1 
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(Ser555/Ser757) , mTOR, Raptor, P-Rb (Ser780), Rb, Cyclin D1, Cyclin A2, Rictor, actin 
were obtained from Cell Signaling. Glucose-free DMEM was from Invitrogen (11966-025). 
Dialyzed fetal bovine serum (F0392) was obtained from Sigma-Aldrich. siRNAs targeting 
LKB1 (sc-35816), AMPK (sc-45312), Raptor (sc-44069), mTOR (sc-35409) were 
obtained from Santa Cruz Biotechnology; and siRNAs targeting Rheb (M-009692-02-
0005), PLD1 (M-009413-00-0010), PLD2 (M-005064-01-0010) were obtained from 
Dharmacon. AICAR and compound C were obtained from Tocris Bioscience.  PLD 
inhibitors for PLD1 (VU0379595) and PLD2 (VU0285655-1), and PA (1-palmitoyl 2-
oleoyl), PS (1-palmitoyl-2oleoyl-sn-Glycero-3-Phospho-L-Serine) in chloroform were 
purchased from Avanti-Polaris Lipids. Antibody against PCNA and siRNA targeting Rictor 
(sc-61478), control siRNA were obtained from Santa Cruz Biotechnology. AICAR, FK506 
was obtained from Tocris Bioscience. 
2.3 Plasmids 
Plasmids for transient transfections were obtained from the following sources: pcDNA3.1 
control plasmid was obtained from Invitrogen. The plasmid expression vectors for HA-
tagged catalytically inactive PLD1 and PLD2 (pCGN-PLD1-K898R) and pCGN-PLD2-
K758R) were generous gifts from Dr. Michael Frohman (SUNY-Stony Brook, NY).  Vector 
expressing mutant K-Ras (G12V) was obtained from Missouri S&T cDNA Resource 
Center, Rolla, MO, USA. 
2.4 siRNA 
Cells were plated on 6-well plates at 30% confluence in medium containing 10% serum. 
After 24 h, cells were transfected with siRNA at 100nM concentration using Lipofectamine 
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RNAiMAX   (Invitrogen)  according   to  manufacturer’s   instructions.  After  6  h,   the  medium 
was changed to fresh medium containing 10% serum and 48 h later, cells were lysed and 
analyzed by Western blot. 
2.5 Western Blot Analysis 
Proteins were extracted from cultured cells in M-PER (Thermo Scientific, 78501).  Equal 
amounts of proteins were subjected to SDS-PAGE on poly-acrylamide separating gels.  
Electrophoresed proteins were then transferred to nitrocellulose membrane.  After 
transfer, membranes were blocked in an isotonic solution containing 5% non-fat dry milk 
in PBS.  Membranes were then incubated with primary antibodies as described in the 
text.  Depending on the origin of the primary antibody, either anti-mouse or anti-rabbit 
HRP conjugated IgG was used for detection using ECL system (Pierce). Relative protein 
level of AMPK phosphorylation were normalized to AMPK and quantified using LI-COR 
image studio software.  
2.6 Flow cytometric analysis 
Cultured cells were washed and trypsinized.  Cell suspensions were recovered and 
resuspended in the following fixing solution: 7ml 1X phosphate buffered saline, 2% bovine 
serum albumin, 5mM EDTA, 0.1% NaN3.  3ml of 100% ethanol was added drop wise. 
Fixed cells were centrifuged, washed, and then resuspended in 500µl sorting buffer: 1X 
phosphate buffered saline, 0.1% Triton-X 100, 2% bovine serum albumin, 5mM EDTA, 
40µg/ml propidium iodide, 100µg/ml RNAse A, and incubated at 37C for 30 min.  The 
cells were filtered through 70-µm mesh to remove cell aggregates. The DNA content was 
analyzed by flow cytometry (FACSCalibur; Becton Dickinson), and percentages of cells 
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within each phase of the cell cycle were determined using WinCycle software (Phoenix 
Flow Systems). 
2.7 Cell proliferation assay 
At indicated times, cells in six-well plates were washed once with PBS, trypsinized with 
500 µl trypsin, resuspended in 500 µl complete medium.  The cells were stained using 
0.1% crystal violet solution (Sigma), and then counted twice using hemocytometer. 
2.8 Trypan blue exclusion cell viability assay 
At indicated time points post-treatment, floating and adherent cells were collected and 
pelleted by centrifugation.  The cell pellet was resuspended in 500 µl PBS, stained using 
500 µl 0.4% trypan blue dye (Sigma), and incubated at room temperature for 10 min.  
Both dead (stained) and live (unstained) cells were counted twice using hemocytometer, 
and percent non-viable cells was determined from dividing dead cells by total number of 
cells. 
2.9 Preparation of PA 
Immediately before use, the appropriate amount of PA was dried under nitrogen and 
resuspended by vortexing briefly in DPBS (SAFC Biosciences, 59321C).  The lipid 
suspension was then sonicated in a water bath sonicator for 5 min. The resulting PA 
suspension was  immediately  added  to  cell  culture  to  a  final  concentration  of  300μM.  Cells  
were lysed after 45 minutes of PA stimulation. PS preparation was also done by following 




2.10 PLD Activity 
PLD activity was determined by accumulation of the transphosphatidylation product [3H]-
phosphatidylbutanol as described previously (85).  Lipid membranes were labeled with 
[3H]-myristic  acid  (60  Ci/mmol;;  1.5  μCi/ml; Perkin-Elmer) for 4 hours. 1-BtOH was added 
for 20 min before lipids where collected. Lipids were extracted and separated by thin layer 
chromatography along with phosphatidylbutanol standard (Enzo Life Sciences, BML-
ST401-0050).  The phosphatidylbutanol fraction was identified through co-migration with 
standards and the levels of the PLD product [3H]-phosphatidylbutanol was determined by 
scintillation counting after scraping the phosphatidylbutanol band from thin layer 
chromatography plates. Error bars for PLD assays represent S.D. values for at least two 
independent experiments. P values  were  calculated  using  a  paired  student’s   t-test, two 
tailed. 
2.11 Immunoprecipitation 
Cells were grown in 10-cm-diameter plates. Immediately before lysing, culture plates 
were rinsed once with cold PBS and lysed on ice for 30 min in 500µl of ice-cold 3-[(3-
cholamidopropyl) - dimethylammonio]-1-propanesulfonate (CHAPS) immunoprecipitation 
buffer (40 mM HEPES [pH 7.5], 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 
mM glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, protease inhibitors 
[Millipore]) containing 0.3% CHAPS.  A 500µg sample of protein was then incubated with 
appropriate antibodies, and the immunoprecipitates were recovered 16 h later with protein 
G-Sepharose.  The immunoprecipitates were then subjected to Western blot analysis 











Blocking anaplerotic entry of glutamine to TCA 










3.1.   Introduction 
          Metabolic dysregulation is an emerging hallmark in cancer.(1)  Coupling 
oncogenesis with the needs of proliferative metabolism, several oncogenes that cause 
cellular transformation also upregulate glycolytic enzymes and promote metabolic 
reprogramming.(4,86)  In order to meet increased anabolic demand, cancer cells display 
elevated levels of glucose uptake.  However, instead of complete oxidation of glucose 
through the tricarboxylic acid (TCA) cycle, most cancer cells convert glucose to lactate 
through a process known as aerobic glycolysis.(87)  This metabolic transformation was 
first described by Otto Warburg in the early 1920s and named Warburg effect.(88)  It has 
been proposed that less efficient utilization of glucose for ATP generation is overcome by 
a marked increase in glucose uptake.(2)  Another metabolic shift is the utilization of the 
TCA cycle intermediate citrate for cytosolic generation of acetyl-CoA.  After conversion of 
the glycolytic product pyruvate to acetyl-CoA in the mitochondria, there is a condensation 
reaction with oxaloacetate to generate citrate, which exits the mitochondria where it is 
converted back to oxaloacetate and acetyl-CoA, which can then be used for fatty acid 
synthesis.  This creates a need for anaplerotic replenishment of TCA cycle intermediate 
that can regenerate oxaloacetate.  The most common source for anaplerosis is glutamine 
(Q), which can be successively deaminated in two steps to produce -ketoglutarate – 
allowing for the maintenance of TCA cycle function.(4)  The Myc oncogene has been 
shown to upregulate glutaminolysis leading to Q addiction in cancer cells.(89,90)  While 
Q has been reported to play pleiotropic roles in tumor proliferation, the impact of Q 
deprivation on cancer cell cycle progression is less well characterized.(91,92)  This is 
further complicated by the differential response of cancer cells to Q deprivation, which 
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likely depends on the mutations they harbor.  For instance, cancer cells with Myc 
overexpression undergo apoptotic cell death in response to Q depletion.(93)  On the other 
hand, in K-Ras overexpressing NIH 3T3 mouse fibroblasts, Q deprivation was shown to 
cause abortive S-phase.(9)  Additionally, we recently reported that some cancer cell lines 
bypass a Q-dependent G1 cell cycle checkpoint and arrest in S- and G2/M-phase of the 
cell cycle upon Q deprivation.(12) 
3.1.1 Purpose of the study in this chapter 
In this report, we demonstrate that cancer cells harboring K-Ras mutations arrest 
in S- and G2/M-phase of cell cycle rather than G1.  Significantly we also show that this 
differential sensitivity to Q in K-Ras mutant cancer cells can be exploited using cell cycle 
phase specific cytotoxic drugs.  Our study provides proof-of-principle that cancers with 
specific genetic defects and dysregulated metabolic cell cycle checkpoints can create a 
synthetic lethality to chemotherapeutic drugs and offer novel therapeutic options. 
3.2   Results 
3.2.1 Glutamine deprivation causes S- and G2/M-phase arrest        
K-Ras mutant cancer cells 
          Glutamine deprivation causes G1 cell cycle arrest in non-transformed primary cells 
(12).We previously reported that MDA-MB-231 breast and Panc-1 pancreatic cancer cell 
lines fail to arrest in late-G1 upon Q or essential amino acid deprivation.(12)  We therefore 
screened several cancer cell lines to identify underlying genetic mutations that override 
the Q-mediated G1 checkpoint.  As seen in Figure 3.1A, Q deprivation for 48 hr caused 
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significant accumulation of cells in G1 phase at the expense of S- and G2/M-phase cells 
in MCF7 breast, and DU-145 and LNCaP prostate cancer cell lines.  On the other hand, 
Q deprivation led to an increase primarily in S-phase cells and a reduction in G1-phase 
cells in MDA-MB-231 breast, PANC-1 pancreatic, and Calu-1 lung cancer cells.  The cell 
lines that failed to arrest in G1 upon Q deprivation all harbor oncogenic K-Ras mutations 
(Figure 3.1A).  The failure to arrest in G1 upon Q deprivation in these K-Ras mutant 
cancer cell lines was neither tissue specific nor K-Ras mutation site specific (Figure 3.1A).  
Since amino acid deprivation has been implicated in mTOR signaling, we also evaluated 
the impact of Q deprivation on mTOR substrate phosphorylation.  While Q deprivation 
caused a modest reduction in S6 kinase phosphorylation, there were no significant 
differences between the cells that arrested in G1 and those that arrested in S- and G2/M-
phase (Figure 3.2).  However, there were elevated levels of Akt phosphorylation at 
Ser473 and Thr 308 observed with Q deprivation in the mutant K-Ras-driven cancer cells 
that is concomitant with non-G1 arrest.  This observation is consistent with a recent report 
that phosphorylation of Akt occurs predominantly as cells progress into S-phase.(94)  We 
also looked at the impact of Q deprivation on the cell cycle progression markers cyclins 
D, E, A, and B, phospho-Rb, and p27 protein levels.  As shown in Figure 3.2, Q 
deprivation in the cancer cells with wild type K-Ras had very little impact on anything other 
than cyclin B, which was lower in the Q-deprived cells.  In the cells with mutant Ras, there 
were subtle reductions in cyclins D and E, phospho-Rb, and p27 levels, with a 
concomitant increase in S-phase marker cyclin A.  The reduction in G1 cell cycle markers 
in K-Ras mutant cancer cells is consistent with a non-G1 arrest observed by FACS 
analysis (Figure 3.1A); however, they do not provide insight into how K-Ras-driven cancer 
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cells avoid G1 arrest.  To establish that Q deprivation was not merely prolonging S-phase 
and thereby causing an increase in the percentage of cells in S-phase, we performed cell 
proliferation assay.  In all the cell lines tested, there was a significant loss of cell 
proliferation upon Q deprivation (Figure 3.1B).  The data in Figure 3.1 reveal a correlation 
between dysregulated Q-mediated G1 cell cycle arrest and K-Ras mutation. 
 
 






               
Figure 3.1.  Glutamine deprivation causes S- and G2/M-phase arrest in K-Ras mutant 
cancer cells. A, MCF7 breast, DU-145 prostate, LNCaP prostate, MDA-MB-231 
breast Panc-1 pancreatic, and Calu-1 lung cancer cells (obtained from the 
American Type Culture Collection, Manassas, VA, USA) were plated at 30% 
confluence in 10-cm plates in complete media (CM) containing 10% serum.  After 
24 hr, the cells were shifted to CM or medium lacking Q for 48 hr.  Both CM and –Q 
medium contained 10% dialyzed FBS (F0392, Sigma-Aldrich, St. Louis, MO, USA).  
After 48 hr, the cells were harvested and analyzed for cell cycle distribution by 
measuring DNA content/cell as described previously.(12)  The error bars represent 
standard error of mean for experiments repeated four times.  The mutations 
present in the cancer cell lines were obtained from the Sanger Institute COSMIC 
database (95) and the Cancer Cell Line Encyclopedia.(96) B, Cells were plated at 
20% confluence in six-well plates in CM containing 10% serum.  After 24 hr (day 1), 
cells were shifted to CM or medium lacking Q.  Cells were harvested at indicated 
time points, stained using crystal violet, and quantified by light microscopy.  Error 







Fig 3.2: Effect of glutamine deprivation on PI3K/mTOR pathway and cell cycle 
regulatory proteins in K-Ras WT and mutant cancer cell lines. A,  Cells were plated 
at 30% confluence in 10-cm plates in complete media containing 10% serum for 24 
hr, at which time they were shifted to CM or medium lacking Q for 4 hr.  The cells 
were subsequently harvested and cell lysates were collected.  The indicated 
protein or phosphoprotein levels were determined by Western blot analysis.  B,  
The cells were plated and treated as in A for 48 hr, at which time cells were 
harvested, lysed, and analyzed for protein levels using Western blot.  The data 
shown are representative of experiments repeated two times. 
 
3.2.2 Override of Q-dependent G1 checkpoint requires activation 
of multiple signaling pathways 
          Based on elegant studies by Weinberg and colleagues on the minimal genetic 





cooperating genetic mutations in human cancer cells impact on signaling pathways that 
lead to passage through two major G1 cell cycle checkpoints(99) that have both been 
referred to as the restriction point.(100)  The first checkpoint is in mid-G1 and is 
dependent on growth factors and facilitates passage through a checkpoint regulated by 
cyclin D and ERK; the second checkpoint is dependent on nutrients (including Q) and is 
regulated by cyclin E and mTOR.(12)  Interestingly, both of these pathways can be 
activated by mutant K-Ras (Figure 3.3A).(101,102)  To investigate if either or both of 
these key regulatory pathways are critical for overriding the Q-dependent G1 checkpoint, 
we investigated whether we could restore G1 arrest in response to Q deprivation by 
pharmacological suppression of the Raf/Mek/ERK and the phosphatidylinositol-3-kinase 
(PI3K)/Akt/mTOR (mammalian target of rapamycin) pathways (Figure 3.3A).  We 
evaluated the effect of U0126 (Mek inhibitor) and Torin1 (mTOR inhibitor) on Q-induced 
cell cycle arrest in MDA-MB-231 and Panc1 cells. As shown in Figure 3.3B, U0126 and 
Torin1 suppressed the phosphorylation of the Mek and mTOR substrates ERK and S6 
kinase respectively in both the MDA-MB-231 and Panc1 cells.  As shown in Figure 3.3C, 
in the absence of Q, S-phase arrest was observed as in Figure 3.1 in the MDA-MB-231 
cells.  Neither U0126 nor Torin1, by itself, reverted the cells to G1 arrest upon Q 
deprivation.  However, treatment with U0126 and Torin1 together did revert the MDA-MB-
231 cells to G1 arrest in the absence of Q (Figure 3.3C).  Similar results were obtained 
when we used the PI3K inhibitor wortmannin instead of Torin1 (Figure 3.3G).  We also 
evaluated the impact of U0126 and Torin1 on Q-induced cell cycle arrest in the Panc-1 
cells, which arrested in both S- and G2/M phase.  Unlike the MDA-MB-231 cells, the 
Panc-1 cells were largely reverted to G1 arrest with only Torin1.  U0126 did not do much 
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by itself and marginally improved G1 arrest when combined with Torin1 (Figure 3.3D).  
The Panc1 cells interestingly still remained arrested in G2/M when treated with Torin1 – 
indicating a differential mechanism for G2/M arrest for the MDA-MB-231 and Panc1 cells. 
We next examined the MCF7 cells, which do not have a K-Ras mutation and arrest 
in G1 in response to Q deprivation.  These cells were treated with the tumor-promoting 
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), which has been shown to 
stimulate the Raf/Mek/ERK pathway,(103) which is commonly activated by mutant K-Ras.  
As shown in Figure 3.3E, TPA treatment caused a shift from G1 to S-phase arrest in 
response to Q deprivation.  This change in arrest pattern could be reverted to G1 arrest 
with U0126, but not with Torin1 – indicating that it was activation of the ERK pathway that 
was responsible.  
The data in Figures 3.1 and 3.3E reveal a correlation between K-Ras mutation or 
activation of the Raf/Mek/ERK pathway and dysregulated G1 cell cycle progression 
through a Q-dependent checkpoint.  We therefore investigated whether mutant K-Ras 
alone is sufficient to override the Q-dependent G1 checkpoint.  We introduced a vector 
that expresses mutant K-Ras (G12V) into the immortalized human diploid fibroblast cell 
line BJ-hTERT(104) and evaluated the impact of Q deprivation on cell cycle progression.  
As shown in Figure 3.3F, mutant K-Ras, by itself, failed to override G1 cell cycle arrest – 
indicating that additional genetic alterations in the cancer cells are required for 
dysregulating the Q-dependent G1 checkpoint.  However, mutant Ras has also been 
reported to induce senescence in primary cells.(105)  Weinberg and colleagues reported 
previously that mutant Ras in combination with TPA induces a transformed phenotype in 
primary cells.(106)  We therefore investigated the effect of mutant K-Ras in combination 
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with TPA on cell cycle progression when cells were depleted of Q.  As shown in Figure 
3.3F, the combination of mutant K-Ras and TPA resulted in S- and G2/M-phase arrest 
upon Q deprivation rather than G1.  Collectively, the data in Figure 3.3 reveal that while 
mutant K-Ras, by itself, is not sufficient to cause override of the Q-dependent G1 cell 
cycle checkpoint, override can be achieved by cooperating genetic alterations or by 







                 
 
Figure 3.3.  Override of Q-dependent G1 checkpoint requires activation of multiple 
signaling pathways.  A, Schematic diagram of the Raf /Mek /ERK and 
PI3K/Akt/mTOR signaling pathways that regulate distinct G1 cell cycle 
checkpoints.(12)  B, MDA-MB-231 and Panc1 cells were plated at 30% confluence 
in 10-cm plates in CM containing 10% serum.  After 24 hr, the cells were treated 
with 10 µM U0126 (Cell Signaling Technology, Danvers, MA, USA) and/or 250 nM 
Torin1 (Tocris Bioscience, Bristol, UK) as indicated for 4 hr at which time cell 
lysates were prepared and used for Western blot analysis of the levels of phospho-
Akt (S473), phospho-S6 kinase (S6K) (T389), phospho-ERK1/2 (T202/Y204), Akt, 
S6K, ERK1/2, and actin (antibodies all from Cell Signaling Technology).  The data 







231 and Panc1 cells were plated as in B.  After 24 hr, the cells were shifted to CM 
or medium lacking Q and treated with 10 µM U0126 and/or 250 nM Torin1 for 48 hr.  
The cells were then analyzed by flow cytometry as in Figure 1.  Error bars represent 
standard error of mean for the experiment repeated four times.  E, MCF7 cells were 
prepared as in C-D, and evaluated similarly as for the MDA-MB-231 and Panc1 cells 
except that cells were also treated with 100 nM TPA (Cell Signaling Technology) as 
indicated concomitantly with U0126 or Torin1.  F, BJ-hTERT human diploid 
fibroblasts (obtained from ATCC) were transfected with either mock control or a 
vector expressing mutant K-Ras (G12V; obtained from Missouri S&T cDNA 
Resource Center, Rolla, MO, USA) using PolyFect transfection reagent (Qiagen, 
Germantown,   MD,   USA)   per   manufacturer’s   recommendations.      K-Ras G12V 
overexpression and activation of downstream phospho-ERK was confirmed by 
Western blot analysis.  The cells were then put in either complete medium (CM) or 
in medium lacking Q for 48 hr, at which time cell cycle status was determined as in 
Figure 3.1A.  TPA (100 nM) was added where indicated at the time of Q withdrawal.  
Error bars represent standard error of mean for experiments repeated three times. 
G, MDA-MB-231 cells were plated at 30% confluence in 10 cm plates in CM 
containing 10% serum. After 24 hr., the cells were shifted to CM or media lacking 
Q and treated with 10uM U0126 (Cell Signaling Technology, Danvers, MA, USA) 
and/or 1uM Wortmannin (Sigma-Aldrich) for 48 hr. The cells were analyzed by flow 
cytometry as in Fig 3.1A.Error bars represent standard error of mean for the 
experiment repeated two times. 
 
3.2.3 Glutamine deprivation sensitizes K-Ras mutant cancer cells 
to phase-specific cytotoxic drugs 
          We next examined whether the differential cell cycle arrest observed with Q 
deprivation could create synthetic lethality to phase specific cytotoxic drugs in K-Ras 
mutant cancer cells.  To specifically target the S-phase arrested cells, we used 
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capecitabine, a pro-drug that is converted enzymatically to 5-fluorouracil and elicits a DNA 
damage response leading to apoptosis.(107)  To target G2/M-phase arrested cells, we 
used paclitaxel, which stabilizes microtubules and induces apoptotic cell death in the 
mitotic phase.(108)  As seen in Figures 3.4A-D, Q deprivation alone led to a modest 
increase in nonviable cells in both K-Ras wild type and K-Ras mutant cancer cell lines.  
In the K-Ras wild type cell lines, addition of capecitabine or paclitaxel to Q-deprived cells 
did not cause significant increases in non-viable cells compared to controls (Figures 3.4A 
and 3.4B).  However, in the K-Ras mutant MDA-MB-231 and PANC-1 cells, Q deprivation 
followed by treatment with either capecitabine or paclitaxel caused a significant increase 
in the nonviable cells (Figures 3.4C and 3.4D).  Thus, in K-Ras mutant cancer cell lines, 
Q deprivation creates a synthetic lethality for the cell cycle phase specific cytotoxic drugs.  
There was a somewhat elevated background of cell death with Q deprivation in the MDA-
MB-231 cells, but there are very stark differences between the sensitivity of the cells 
harboring K-Ras mutations with those that do not.  
 As shown in Figure 3.3, we were able to get MCF7 cells and BJ cells expressing 
mutant K-Ras to bypass the G1 Q-dependent cell cycle checkpoint and arrest in S- and/or 
G2/M phases when treated with TPA.  We therefore examined whether these cells 
became sensitive to capecitabine and paclitaxel.  As shown in Figure 3.4E and 3.4F, both 
MCF7 and BJ-K-Ras cells, upon Q depletion, became sensitive to capecitabine and 
paclitaxel when treated with TPA.  Thus, it is the arrest in S and G2/M that sensitizes cells 






Figure 3.4 Glutamine deprivation sensitizes K-Ras mutated cancer cells to phase-
specific cytotoxic drugs.  MCF7 A, DU-145 B, MDA-MB-231 C, and Panc1 D, cells 
were plated at 20% confluence in six-well plates in complete media (CM) containing 






for 48 hr.  After 48 hr, the cells were additionally treated with 50 nM paclitaxel (Pac) 
or 1 µg/ml capecitabine (Cap) (both from Sigma-Aldrich) for 24 hr.  Percent cell 
viability was determined using trypan blue dye exclusion assay as described 
previously.(109)  MCF7 E and BJ-K-Ras F, cells were placed in CM or medium 
lacking Q for 48 hr in the presence and absence of 100 nM TPA as indicated.  After 
48 hr, the cells were additionally treated with paclitaxel and capecitabine for 24 hr 
and cell viability was determined as in (A-D). Error bars represent the standard 
error of the mean for experiments repeated three times. 
 
3.2.4 Pharmacological inhibition of Q anaplerosis sensitizes K-Ras 
mutant cancer cells to cytotoxic drugs 
          Glutamine, via anaplerotic entry to the TCA cycle, replenishes the intermediates 
lost by the exit of citrate from the mitochondria for fatty acid and cholesterol 
biosynthesis.(5)  Glutaminase catalyzes the deamination of Q to generate glutamate.  
Glutamate can then be converted to -ketoglutarate by either glutamate dehydrogenase 
or transaminase.  Kimmelman and colleagues recently reported that K-Ras-driven 
pancreatic cancer cells preferentially utilize the transaminase pathway for anaplerotic 
glutamine utilization.(11)  In the transaminase pathway, glutamate acts as an amino donor 
to oxaloacetate – a reaction catalyzed by glutamate oxaloacetate transaminase (GOT), 
which   generates   aspartate   and   α-ketoglutarate (schematic shown in Figure 3.5A).  
Anaplerotic entry of Q into the TCA cycle can be inhibited by aminooxyacetate (AOA) – a 
pan-transaminase inhibitor, which inhibits GOT and consequently the entry of glutamine 
into the TCA cycle.(110,111)  Treatment of both MCF-7 and MDA-MB-231 cells with AOA 
for 48 hr led to morphological changes similar to that observed with Q deprivation (Figure 
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3.5B).  As seen in Figure 3.5C, AOA treatment caused G1 arrest in the MCF-7 cells and 
S- and G2/M-phase arrest in the MDA-MB-231 cells and also blocked proliferation (Figure 
3.5D) as was observed with Q deprivation in Figure 3.5A and B – indicating that AOA 
mimics Q deprivation in both cell types.  We also investigated whether the effect of AOA 
on cell cycle progression could be reversed by providing cell permeable analogues of -
ketoglutarate and aspartate – the products of the transamination reaction between 
glutamate and oxaloacetate.  Dimethyl--ketoglutarate (DMKG) and -methyl-aspartate 
(-MD) were included along with AOA for the MDA-MB-231 cells.  As shown in Figure 
3.5E, neither compound by itself was able to completely reverse S- and G2/M arrest seen 
in the MDA-MB-231 cells, however the combination of both DMKG and -MD did reverse 
the S- and G2/M arrest in these cells – indicating that generating both -ketoglutarate 
and aspartate in the transaminase reaction is critical for passing through S- and G2/M 
phases.  This finding is similar to that observed by Kimmelman and colleagues who 
showed a requirement for both -ketoglutarate and non-essential amino acids (which 
included aspartate) for colony formation by pancreatic cancer cells.  The need for 
aspartate as well as -ketoglutarate indicates that the aspartate generated by the 
transaminase reaction is important.  Kimmelman and colleagues (11) demonstrated a 
critical need for conversion of aspartate  oxaloacetate, followed by conversion of 
oxaloacetate  malate, and then oxidative decarboxylation to pyruvate by malic enzyme 
in order to generate NADPH and maintain redox balance.  However, a substantial amount 
of anaplerotic Q is converted to fatty acids.(87)  Thus, the aspartate generated by the 
transaminase reaction between glutamate and oxaloacetate is likely destined to re-enter 
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the TCA cycle via conversion to oxaloacetate followed by condensation with acetyl-CoA 
to form citrate (see Figure 3.5A). 
We further investigated whether AOA treatment would mimic Q deprivation to 
create the synthetic lethality observed with cell cycle phase-specific cytotoxic drugs in K-
Ras mutant cancer cells.  AOA treatment by itself led to minimal increase in nonviable 
cells in both MCF-7 and MDA-MB-231 cells (Figure 3.5F).  AOA treatment alone also did 
not induce significant increases in cleaved PARP (Figure 3.5F), an indicator of apoptosis 
– suggesting that AOA has low cytotoxicity.  This is important in that AOA also inhibits 
alanine transaminase as well.(11)  Similar to what was observed with Q deprivation, the 
combination of AOA and the cytotoxic drugs did not increase the percentage of nonviable 
cells and cleaved PARP levels in MCF-7 cells (Figure 3.5D).  However, the combination 
of AOA and the cytotoxic drugs caused a significant increase in nonviable cells and 
cleaved PARP levels in MDA-MB-231 cells (Figure 3.5D).  These data indicate that in K-
Ras mutant cancer cells, pharmacological inhibition of anaplerotic entry of Q into the TCA 
cycle mimics Q deprivation to produce aberrant cell cycle arrest creating synthetic lethality 
to cell cycle phase specific cytotoxic drugs. 
Metabolic transformation is an emerging paradigm in cancer biology(1).  Glutamine 
has been suggested to play pleiotropic roles in tumor proliferation, and several oncogenes 
have been shown to promote aerobic glycolysis and Q addiction in cancer cells.(7,92)  
We previously reported that while most cells arrest in late G1 in response to Q deprivation, 
some cancer cell lines arrested in S and G2/M.(12)  An extension of this study revealed 
a correlation between G1 Q-checkpoint override in human cancer cell lines with K-Ras 
mutations.  Upon Q deprivation, cancer cell lines harboring K-Ras mutations arrested in 
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S and G2/M rather than G1.  Whether there are actual Q-sensitive checkpoints in S- and 
G2/M phases is not clear from data presented here, however it is clear from Figure 3.1B 
that cell number is not increasing and therefore cells are stopping progression in S and 
G2/M phases and it is here that they are sensitive to cytotoxic drugs.  Of significance, Q 
deprivation created a synthetic lethality for compounds that selectively target cells in S 
and G2/M phases of the cell cycle.  Importantly, Q deprivation could be mimicked with 
AOA – a compound that interferes with the transaminase pathway for anaplerotic 
conversion of Q into the TCA cycle intermediate -ketoglutarate.  The ability of AOA to 
mimic Q deprivation is consistent with the recent report that K-Ras-driven pancreatic cells 
preferentially use the transaminase over the glutamate dehydrogenase pathway for 
generating -ketoglutarate.(11)  Thus, it is possible that a combination of drugs that block 
the generation of -ketoglutarate via transamination and kill cells in S- and/or G2/M phase 
could be used to target K-Ras driven cancers(Figure 3.5G).   






Figure 3.5 Pharmacological inhibition of Q anaplerosis sensitizes K-Ras mutant 
cancer cells to cytotoxic drugs.  A, Schematic overview of anaplerotic Q utilization.  







to -ketoglutarate via transamination catalyzed by GOT, which uses oxaloacetate 
as the amino group acceptor to generate aspartate.  AOA inhibits GOT and 
therefore suppresses generation of -ketoglutarate from Q-derived glutamate.  
Aspartate is critical for redox balance and NAPDH production and the generation 
of citrate for fatty acid synthesis.  B, Cells were plated at 20% confluence in 10-cm 
plates in complete medium (CM).  After 24 hr, cells were shifted to CM, or medium 
lacking Q, or CM containing 0.5 mM AOA (C13408, Sigma-Aldrich) for 48 hr – at 
which time the cells were observed using phase-contrast microscopy.  C, MCF7 
and MDA-MB-231 cells were plated and treated as in (b) for 48 hr, at which time 
cells were analyzed for cell cycle distribution as in Figure 1.  In addition to AOA, 
the MDA-MB-231 cells were treated with cell permeable analogues of -
ketoglutarate (DMKG; 4 mM) (349631, Sigma-Aldrich) and aspartate (-MD; 4 mM) 
(A8921, Sigma-Aldrich).  Error bars represent standard error of mean for 
experiments repeated three times.  D, Cells were plated and treated as in B, 
harvested at indicated time points, and scored after staining with crystal violet 
using light microscopy.  Error bars represent the standard error of the mean for 
experiments repeated three times.  E, MCF7 and MDA-MB-231 cells were plated as 
in B, and shifted to CM or treated with 0.5 mM AOA for 48 hr.  The cells were 
additionally treated with 50 nM Pac or 1 µg/ml Cap for 24 hr, at which time the 
percentage non-viable cells were determined using trypan blue exclusion assay.  
Error bars represent the standard error of mean for experiments repeated three 
times.  Cell lysates were also collected, and the levels of cleaved PARP (antibody 
from Cell Signaling) were determined by Western blot analysis.  Data shown are 
representative of experiments repeated two times.  F, Model depicting that AOA 
treatment mimics Q deprivation causing G1 cell cycle arrest in K-Ras wild type cells 
and S- and G2/M-phase arrest in K-Ras mutant human cancer cell lines, which 
creates synthetic lethality to cell cycle phase-specific cytotoxic drugs causing 





3.3   Discussion 
While there was a correlation between cancer cells harboring K-Ras mutations and 
override of the Q-dependent G1 cell cycle checkpoint, K-Ras, by itself, was not sufficient 
to induce override of the Q-dependent G1 checkpoint in immortalized BJ cells.  However, 
the inability to observe bypass of the Q-dependent G1 checkpoint was likely due to the 
induction of senescence by mutant K-Ras.(105)  However, if TPA, which cooperates with 
mutant Ras to transform primary cells(106) was provided, the cells bypassed the G1 
checkpoint and arrested in S- and G2/M phases and were now sensitive to capecitabine 
and paclitaxel.  In addition, we observe override of the Q-dependent G1 cell cycle 
checkpoint by activating the ERK pathway in MCF-7 cells – indicating that bypass could 
be achieved by activating this K-Ras effector pathway.  Panc-1 pancreatic cancer cells 
that harbor a K-Ras mutation arrested in S- and G2/M phase with Q deprivation, but could 
largely be reverted to G1 arrest with only mTOR suppression.  Thus, it is clear that 
override of the Q-mediated G1 checkpoint is complex involving more than one signaling 
pathway.  Combined inhibition of two key regulators of G1 cell cycle progression – ERK 
and mTOR – reverted override of the Q-mediated G1 checkpoint, indicating that override 
is dependent on two key signaling nodes implicated at two distinct regulatory G1 
checkpoints that have both been referred to as the restriction point.(12)  Whether this 
phenomena is absolutely dependent on the K-Ras or K-Ras effector signals is not clear 
– nor is it clear that all cancer cells with K-Ras mutations will override the Q-dependent 
checkpoint.  In fact the DU-145 prostate cancer cells used in this study harbors an unusual 
UBE2L3-KRas fusion protein, knockdown of which was shown to attenuate cell invasion 
and xenograft growth(112), but still arrested in G1 in response to Q deprivation as seen 
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in Figure 3.1a.  Thus, while the connection between activated K-Ras and override of the 
Q-dependent G1 checkpoint is not likely absolute, the correlation observed here with 
human cancer cell lines harboring K-Ras mutations and a synthetic lethal sensitivity to 
paclitaxel and capecitabine suggests novel strategies for therapeutic intervention in a 
class of cancers considered undruggable. 
To test the hypothesis that Gln deprivation in K-Ras-driven cancer cells could 
create sensitivity to cytotoxic compounds, we deprived K-Ras-driven cancer cells of Gln 
and examined sensitivity to capecitabine, which interferes with DNA synthesis; and 
paclitaxel, which interferes with microtubule breakdown during mitosis.  Both capecitabine 
and paclitaxel induced apoptosis in K-Ras-driven, but not in cancer cells lacking K-Ras 
mutation that arrested in G1 upon Gln depletion.  Clearly, Gln deprivation is not a viable 
therapeutic option; however, interfering with anaplerotic utilization of Gln is possible.(113)  
Kimmelman and colleagues recently reported that Gln is utilized in K-Ras-driven 
pancreatic cancer cells via a transamination reaction whereby glutamate is deaminated 
to -ketoglutarate with concomitant generation of aspartate from oxaloacetate (11).  Thus, 
in K-Ras-driven cancer cells, the transaminase pathway is apparently preferred over the 
glutamate hydrogenase pathway, which is used when glucose levels are low.(113)  
Consistent with findings reported by the Kimmelman group, we found that the 
transaminase inhibitor aminooxyacetate (AOA) mimicked Gln depletion and created 
sensitivity to capecitabine and paclitaxel in K-Ras-driven cancer cells.  Thus, a 
combination of transaminase inhibitors along with capecitabine and paclitaxel could be a 
viable strategy for treating K-Ras-driven cancers that exploits the ability of K-Ras to 
stimulate override of the Gln-dependent G1 checkpoint.  This approach represents a 
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“synthetic  lethal”  situation(114) whereby activating K-Ras mutations in combination with 
suppressed Gln utilization sensitizes cells to the cytotoxic effects of cell cycle phase-
specific effects of capecitabine and paclitaxel.  
          Thus, after receiving growth factor signals indicating that it is appropriate to divide, 
there are perhaps several late G1 metabolic checkpoints that monitor whether there are 
sufficient nutrients available for the cell to double its mass and divide.(115)  This is shown 
schematically in Figure 3.6.  Importantly, cancer cells harboring K-Ras mutations did not 
arrest in G1 upon Gln deprivation.  Instead, K-Ras-driven cancer cells progress into S- 
and G2/M-phase where they arrested.(116)  Thus, mutant K-Ras confers the ability to 
override the Gln-dependent late G1 checkpoint allowing progression from G1 into S-phase 
in the absence of Gln.  Suppression of the K-Ras downstream effectors mTOR and Erk 
restored G1 arrest in response to Gln deprivation in K-Ras-driven cancer cells – indicating 
that override of the G1 Gln checkpoint was mediated by activation of mTOR and Erk.  
Cells that have committed to divide and progress into S and G2/M are, in general, more 
vulnerable to apoptotic insult.  Thus, K-Ras-driven cancer cells, which override a Gln-
dependent G1 cell cycle checkpoint and arrest in S and G2/M, could be sensitive to 




Figure 3.6 Schematic overview of late G1 metabolic cell cycle checkpoints Adopted from 
(10): The relative positions of the growth factor-dependent Restricition Point and 
late G1 metabolic checkpoints mediated by essential amino acids, Gln and mTOR 
are depicted. 
 
          Oncogenic K-Ras mutations are common in many different cancer types and 
contribute to as many as 30% of all human cancers – including 90% of pancreatic 
cancers(117) - which have a poor prognosis with mortality usually within 6 months of 
detection and a five-year survivability of less than 5%.(118)  K-Ras mutants have 
enhanced binding to GTP and are considered undruggable – due in part to the picomolar 
range for GTP binding.(119)  Thus, targeting K-Ras-driven cancers has been problematic 
– especially for pancreatic cancer, which is likely the deadliest of human cancers.  The 
observation reported here – that inhibition of anaplerotic utilization of Q in K-Ras-driven 
human cancer cell lines leads to cell cycle arrest in S- and G2/M rather than G1 – 
suggests a vulnerability for K-Ras-driven cancers that could be exploited therapeutically.  
We have demonstrated here an enhanced sensitivity to chemotherapeutic agents that 
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target cells in S- and G2/M – providing proof-of-principle for the predicted synthetic 
lethality created by interfering with Q utilization. 
An emerging pattern for Ras-driven tumorigenesis involves changes in nutrient 
utilization as reported here for glutamine and previously by Kimmelman and 
colleagues.(11)  In addition, it was recently reported that Ras-driven cancer cells also 
have special needs for extracellular lipids (85,120) and glutamine.(121)  Significantly, the 
need for exogenously supplied lipids in Ras-driven cancer cells creates a synthetic 
lethality for rapamycin.(85)  Thus, it is conceivable that the altered nutritional and 
metabolic needs by Ras-driven  cancers  may  actually  prove  to  be  an  Achilles’  heel  for  this  
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AMP-activated protein kinase (AMPK) is a critical signaling node that responds to 
cellular energy levels and alters cell metabolism accordingly (76,122).  Altered 
metabolism has become a hallmark of cancer (1); and accordingly, AMPK is 
suppressed in many cancers (76).  The best characterized mechanism for suppressing 
AMPK activity in human cancers is through mutations to the gene encoding liver kinase 
B1 (LKB1) (77).  LKB1 had previously been reported to be a tumor suppressor 
associated with an inherited tumor susceptibility known as Peutz-Jeghers syndrome 
(123,124).  The discovery of the connection between LKB1 and AMPK (82,84,125) 
clearly implicated altered metabolism in cancer.  In response to elevated AMP/ATP 
ratios, AMPK binds AMP and then gets phosphorylated by LKB1. This leads to activated 
AMPK and the suppression of anabolic metabolism and a concomitant shift to catabolic 
events that generate ATP to restore energy homeostasis (76,126). 
In addition to causing a shift from anabolic to catabolic metabolism, AMPK also 
stimulates a p53-dependent G1 cell cycle arrest (127,128).  The LKB1/AMPK pathway 
suppresses mTOR (mammalian/mechanistic target of rapamycin) signaling (129,130).  
Suppression of mTOR also results in G1 cell cycle arrest (12).  A key downstream target 
of AMPK is the tuberous sclerosis complex (TSC) consisting of TSC1 and TSC2.  The 
TSC has a GTPase activating protein (GAP) activity towards the GTPase Ras homolog 
enriched in brain (Rheb) (46).  AMPK phosphorylates TSC2 and activates its GAP activity 
resulting in suppressed Rheb due to the hydrolysis of bound GTP to GDP.   Rheb is a key 
regulator of mTOR complex 1 (mTORC1) (131).  Thus mechanistically, activating AMPK 
could cause cell cycle arrest by suppressing mTOR.  Of interest is that while GTP-bound 
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Rheb is required for mTOR activation, Rheb binds mTOR in a GTP-independent manner 
(132).  However, Rheb binds to, and activates, phospholipase D1 (PLD1) in a GTP-
dependent manner (56).  PLD generates the metabolite phosphatidic acid (PA), which is 
required for the stability and activity of the mTOR complexes mTORC1 and mTORC2 
(54,58).  PLD activity is required for the stimulation of mTOR by growth factors (72) and 
amino acids (55,57).  Thus, a key role for Rheb could be the generation of PA needed for 
mTOR activity.  PLD activity is commonly elevated in human cancer cells and, like mTOR, 
promotes cell cycle progression and survival (71,72).     
4.1.1 Purpose of the study in this chapter 
While the negative impact of AMPK on mTOR has been previously reported (129), much 
less is known about the impact of mTOR on AMPK signals.  We report here that AMPK 
suppresses PLD activity in human cancer cells with elevated PLD activity and that PLD 
and PA suppress AMPK in an mTOR-dependent manner.  This study reveals a means 
for cancer cells to suppress AMPK in order to promote cell proliferation. 
4.2   Results 
4.2.1 Activation of AMPK suppresses PLD activity 
To investigate a connection between PLD and AMPK activities we examined the 
effect of glucose deprivation, which is known to elevate AMPK activity, on PLD activity.  
We used two K-Ras driven human cancer cell lines, MDA-MB-231 breast and Calu-1 lung, 
which we have reported previously to have elevated PLD activity (133,134).  As expected, 
glucose deprivation resulted in elevated phosphorylation of AMPK at the LKB1 site at 
T172 in both the MDA-MB-231 and Calu-1 cells (Fig. 4.1A).  As shown in Fig. 4.1A, 
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glucose deprivation also led to a suppression of the PLD activity in both MDA-MB-231 
and Calu-1 cells.  These data reveal a correlation between elevated AMPK activity and 
suppressed PLD activity. 
AMPK can be activated by AICAR (5-aminoimidazole-4-carboxamide 
ribonucleoside) – a cell-permeable nucleoside that is metabolically converted to  
5-aminoimidazole-4-carboxamide ribonucleoside monophosphate or ZMP by adenosine 
kinase.  ZMP mimics the allosteric effects of AMP on the AMPK system (135).  As shown 
in Fig. 4.1B, AICAR treatment activated AMPK as indicated by increased levels of 
phosphorylated AMPK at the LKB1 site.  Also shown is the AICAR-induced increase in 
the level of phosphorylation of acetyl-CoA carboxylase (ACC) - a substrate of AMPK that 
regulates the synthesis of fatty acids.  We next examined the effect of AICAR on PLD 
activity, and as shown in Fig. 4.1C, AICAR Suppressed the PLD activity in both MDA-MB-
231 and Calu-1 cells.  PLD catalyzes the hydrolysis of phosphatidylcholine to generate 
PA.  We therefore examined the effect of AICAR on MDA-MB-231 and BJ-hTERT cells 
treated with PA.  Of significance, the AICAR-induced increase in the phosphorylation of 
both AMPK and ACC was suppressed by PA treatment (Figs. 4.1D and 4.1F) whereas 
Phosphatidylserine, as a control lipid addition (Fig. 4.1E)  can’t  suppress  the  activation  of  
AMPK upon AICAR treatment. These data further demonstrate that elevated AMPK 
activity suppresses PLD activity and intriguingly suggest that PLD generated PA prevents 
AMPK activation. We also investigated the regulation of AMPK while PLD activity is 
stimulated by phorbol esters, a known activator of PLD. TPA treatment along with AICAR 
diminished the activation of AMPK in MDA-MB-231 cells (Fig. 4.1G). This data further 




Figure 4.1 Activation of AMPK suppresses PLD activity. A, MDA-MB-231 and Calu-
1 cells were plated at 80% confluence in 60mm plates in DMEM containing 10% 
serum. 24 h later the cells were shifted to medium containing either complete 
DMEM or DMEM lacking glucose. Both complete DMEM and DMEM without glucose 
contained 10% dialyzed fetal bovine serum. After 4 hr, cells were harvested and 
lysates were prepared and used for Western blot analysis for the levels of phospho-
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AMPK (P-AMPK), AMPK and actin. For PLD activity assay [3H]-myristic acid was 
added for 4 h in fresh medium to label lipids. 1-BtOH was added for 20 minutes, 
and the amount of the PLD-catalyzed transphosphatidylation product, 
phosphatidyl-butanol, was   determined   as   described   under   “Experimental  
Procedures”.   Values   were   normalized   to   the   levels   of   PLD   activity   in   controls,  
which were given a value of 100%.  B, MDA-MB-231 cells were plated as in A and 
24 h later AICAR (2mM) was added for indicated times. Cells were harvested and 
the levels of P-AMPK, AMPK, phospho-ACC (P-ACC), ACC and actin were 
determined by Western blot analysis. C, MDA-MB-231 and Calu-1 cells were plated 
as in A and AICAR was added for 45 min. The cells were then harvested and the 
PLD activity was determined as in A. D, MDA-MB-231 cells were plated as in B. 
Where  indicated,  cells  were  treated  with  AICAR  and/or  (PA  300μM)  for  45  min.  The  
cells were then harvested and levels of P-AMPK, AMPK, P-ACC, ACC and actin 
were determined as in B. E, MDA-MB-231 cells were plated as in B. Where indicated, 
cells  were  treated  with  AICAR  and/or  (PS  300μM)  for  45  min.  The  cells  were  then  
harvested and levels of P-AMPK, AMPK, P-ACC, ACC and actin were determined 
as in B. F, BJ-hTERT cells were plated as in D. Where indicated cells were treated 
with  AICAR  and/or  (PA  300μM)  for  4hr.  The  cells  were  then  harvested  and  levels  of  
P-AMPK, AMPK, P-ACC, ACC and actin were determined as in D. G, MDA-MB-231 
cells were plated as in D. Where indicated, cells were treated with AICAR and/or 
(TPA  100ɳM)  for  24  hr.  The  cells  were  then  harvested  and  levels  of  P-AMPK, AMPK, 
P-ACC, ACC and actin were determined as in D.  Error bars for PLD assays 
represent S.D. values for at least two independent experiments. The Western blots 
shown are representative of experiments repeated at least two times. The statistical 
significance (P value) was determined by a two-tailed, paired  Student’s t-test. *P ≤  
0.01 compared with control. Relative levels of AMPK, ACC phosphorylation were 





4.2.2 Inhibiting AMPK Increases PLD Activity in a Rheb-dependent 
Manner- The data in Figs. 4.1 indicate that AMPK suppresses PLD activity.  We 
therefore investigated the effect of inhibiting AMPK on PLD activity.  We first examined 
the effect of compound C – a pharmacological inhibitor of AMPK.  As shown in Fig. 4.2A, 
compound C inhibited the phosphorylation of both AMPK and ACC.  Compound C also 
increased the PLD activity in both MDA-MB-231 and Calu-1 cells (Fig. 4.2A).  We also 
suppressed the expression of AMPK and LKB1 using siRNA.  As shown in Fig. 4.2B, 
suppression of either AMPK or LKB1 expression elevated PLD activity in both MDA-MB-
231 and Calu-1 cells.  Thus, activation of AMPK suppresses PLD activity and suppression 
of AMPK elevates PLD activity.  
AMPK phosphorylates TSC2 and activates its GAP activity towards Rheb (46) – 
resulting in the suppression of Rheb.  Rheb binds to and activates PLD1 in a GTP-
dependent manner (56).  We therefore examined whether the elevated PLD activity 
observed in response to suppression of AMPK was dependent on Rheb.  We stimulated 
PLD activity in MDA-MB-231 cells by suppressing AMPK expression with siRNA for 
AMPK as in Fig. 4.2B and then examined the effect of suppressing Rheb expression on 
PLD activity.  As shown in Fig. 4.2C, suppressing Rheb expression with siRNA prevented 
the induction of PLD activity observed with AMPK knockdown with siRNA.  These data 
demonstrate that the increased PLD activity observed with AMPK inhibition was 
dependent upon Rheb. 
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Figure 4.2 Inhibiting AMPK increases PLD activity in a Rheb-dependent manner.  A, 
MDA-MB-231 cells were plated as in Fig 4.1B, and were then treated with Compound 
C  (Com  C)  (20μM)  for  45  min.  The  cells  were  then  harvested  and  levels  of  P-AMPK, 
AMPK, P-ACC, ACC and actin were determined by Western blot analysis.  For PLD 
activity assay MDA-MB-231 and Calu-1 cells were plated and treated with 
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Compound C for 45 min, and the relative PLD activity was then determined as in 
Fig 4.1C. B and C, MDA-MB-231 cells were plated in 6 well plates at 30% confluence 
overnight. The cells were then transfected with siRNAs for either scrambled 
(scram) control siRNA, LKB1 or AMPK (B) or Rheb (C) as indicated. 6 h later, the 
cells were treated with fresh medium containing 10% serum for an additional 48h. 
The cells were then harvested and the levels of LKB1, P-AMPK, AMPK (B), Rheb 
(C) and actin were determined by Western blot analysis. For PLD activity assays, 
Calu-1 (B) and MDA-MB-231 (B, C) cells were plated and transfected with siRNAs 
as mentioned above. After 48 h of siRNA transfection cells were harvested and PLD 
activity was evaluated as in A. Values were normalized to the control scrambled 
siRNAs, which were given a value of 100%. Error bars for PLD assays represent 
S.D. values for at least two independent experiments. The Western blots shown are 
representative of experiments repeated at least two times. The statistical 
significance (P value) was determined by a two-tailed, paired  Student’s t-test. *P ≤  
0.01 compared with control. 
 
4.2.3 Inhibition of PLD Activates AMPK 
PLD catalyzes the hydrolysis of phosphatidylcholine to generate choline and PA, which 
is required for mTOR complex stability (54) and activity (58).  Since mTOR is sensitive to 
the energy status of the cell, we evaluated the effect of suppressing PLD activity on 
AMPK.  We first examined effect of siRNAs for PLD1 and PLD2 on AMPK activity as 
measured by the level of phosphorylated AMPK and ACC.  As shown in Fig 4.3A, 
introduction of PLD 1 and 2 siRNAs led to the suppression of PLD activity and elevated 
the level of both AMPK and ACC phosphorylation.  Similar results were obtained using 
catalytically inactive mutants of PLD1 and PLD2 that act as dominant-negative mutants 
(54) (Fig. 4.3B) or pharmacological inhibitors of PLD1 and PLD2 (Fig. 4.3C).  Importantly, 
the effect of the PLD inhibitors on the phosphorylation of AMPK and ACC could be 
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suppressed if PA was exogenously provided (Figs. 4.3D and 4.3E) – indicating that the 
effect of the inhibitors was due to preventing PA production.  Thus, there appears to be 
reciprocal regulation of PLD by AMPK and AMPK by PLD.        
 
Figure 4.3. Inhibition of PLD activates AMPK   A, MDA-MB-231 cells were plated as 
in Fig 4.2B and were transfected with PLD1 and PLD2 siRNAs or a scrambled 
control siRNA as indicated. 6 h later, the cells were treated with fresh medium 
containing 10% serum for an additional 72h. The cells were then harvested and PLD 
activity   was   evaluated   as   described   under   “Experimental   Procedures”.   Values  
were normalized to the control scrambled siRNAs, which were given a value of 
100%. For Western blot analysis, cells were harvested at 72 hr and levels of P-
AMPK, AMPK, P-ACC, ACC and actin were determined. B, MDA-MB-231 cells were 
plated as in A and were transfected with vectors expressing catalytically inactive 
dominant negative (DN) mutant forms of PLD1 and PLD2. The parental vector 
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pcDNA3.1 was used as control. 48h later, the cells were harvested and levels of P-
AMPK, AMPK, P-ACC and ACC were determined as in A. Expression of PLD 
mutants was evaluated by probing the blots for HA tags on the PLD mutants.  Blots 
were also probed for actin as loading controls.  C, MDA-MB-231 cells were plated 
and  the  PLDi  (PLD1  inhibitor+PLD2  inhibitor,  10μM  each)  were  added  for  1  h  and  
the relative PLD activity was then determined as in Fig 4.1C. For Western blot 
analysis, MDA-MB-231 cells were plated and treated with PLDi for indicated times. 
Cells were harvested and levels of P-AMPK, AMPK, P-ACC, ACC and actin were 
determined as in A. D, MDA-MB-231 cells were plated as in C, were treated with 
PLDi and / or PA for 45 min where indicated. The cells were then harvested and 
levels of P-AMPK, AMPK, P-ACC, ACC and actin were determined as in A. E, Calu-
1 cells were plated and the PLDi (PLD1 inhibitor+PLD2 inhibitor,  10μM  each)  were  
added for 1 h and the relative PLD activity was then determined as in Fig 4.1C. For 
Western blot analysis, Calu-1 cells were plated as in C, were treated with PLDi and 
/ or PA for 45 min where indicated. The cells were then harvested and levels of P-
AMPK, AMPK, P-ACC, ACC and actin were determined as in A. The Western blot 
data are representative of experiments repeated at least two times. Error bars for 
PLD assays represent S.D. values for at least two independent experiments. The 
statistical significance (P value) was determined by a two-tailed, paired  Student’s 
t-test. *P < 0.001 compared with control. Relative levels of AMPK, ACC 
phosphorylation were normalized to total AMPK, total ACC respectively and 
quantified as in Fig 4.1A. 
 
4.2.4 Activation of AMPK by PLD Inhibition is Due to Reduced 
mTORC1 Activity— The data presented in Figs. 4.1-3 reveal a reciprocal regulation 
of AMPK and PLD whereby suppression of AMPK activates PLD, and suppression of PLD 
activates AMPK.  A critical target of PLD and PA is mTOR (71), which like PLD, is 
dependent upon Rheb (46,132).  It was previously reported that rapamycin could increase 
phosphorylation of AMPK and ACC (136).   We therefore examined whether suppression 
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of mTORC1 would, like suppression of PLD, elevate AMPK activity.  We treated MDA-
MB-231 cells with siRNAs for both mTOR and the mTORC1 companion protein Raptor 
and examined the levels of AMPK and ACC phosphorylation.  As shown in Fig. 4.4A, 
suppressing the expression of either mTOR or Raptor led to substantial increases in both 
AMPK and ACC phosphorylation.  We next evaluated the effect of PA on AICAR-induced 
phosphorylation of TSC and the mTOR substrates S6 kinase and eukaryotic initiation 
factor 4E (eIF4E) binding protein 1 (4E-BP1).  As expected, AICAR induced 
phosphorylation of TSC at the AMPK site at S1387 and suppressed phosphorylation of 
the mTORC1 substrates S6 kinase S6 kinase and 4E-BP1 (Fig. 4.4B, left panel)).  
Importantly, the effect of AICAR was reversed if cells were provided with PA – indicating 
that the effect of AICAR was the result of suppressing PLD activation.  However, if the 
expression of either mTOR (Fig. 4.4B, middle panel) or Raptor (Fig. 4.4B, right panel) 
was suppressed with siRNA, PA was unable to reverse the effect of AICAR.  These data 
demonstrate that the presence of PA overcomes the effects of AMPK activation – 
implicating PLD; and importantly, that suppression of mTORC1 overcomes the ability of 
PA to suppress the effect of AICAR.  The inability of PA to overcome the effect of AICAR 
in the absence of mTOR or Raptor indicates that the effect of AICAR on mTORC1 was 
due to the suppression of PLD-stimulated PA production.  The inability of PA to rescue 
the inhibitory effect of AICAR on TSC2 phosphorylation in the absence of either mTOR 
or Raptor supports the hypothesis that the effect of PA was dependent on mTOR. 
We next evaluated the effect of PLD inhibition on autophagy as a readout of mTOR 
suppression. Autophagy is regulated by several kinases including AMPK, a positive 
regulator of autophagy(137).   AICAR   treatment   or   PLD   inhibitors’ treatment induces 
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phosphorylation of ULK1 Ser555, a specific site mediated by activated AMPK (Fig 4.4C). 
Contrary to this both treatments also suppresses the phosphorylation of ULK1 Ser757 
which is mediated by mTOR. These data suggest that inhibition of PLD results in 
autophagy by inducing AMPK-ULK1 (Ser555 phosphorylation) and by suppressing 
mTOR-ULK1 (Ser757 phosphorylation). The effects of AMPK-PLD feedback substantially 
regulates autophagy through mTOR signaling node. Data provided here reveal that PLD 
suppresses autophagy through the mTOR-AMPK-ULK1 signaling pathway. These data 
are consistent with a recent report from Min and colleagues (138), who reported that PLD 
inhibition enhances autophagic flux via ULK1. These data reveal that activation of AMPK 




Figure 4.4 Effects of PLD on AMPK are mediated by mTORC1. A, MDA-MB-231 cells 
were plated as in Fig 3A and were transfected with either mTOR siRNA or Raptor 
siRNA or a scrambled control siRNA as indicated. After 72h of transfection, cells 
were harvested and analyzed for P-AMPK, AMPK, P-ACC, ACC, mTOR, Raptor and 
actin by Western blot analysis. Relative levels of AMPK, ACC phosphorylation were 
normalized to total AMPK, total ACC respectively and quantified as in Fig 4.1A. B, 
MDA-MB-231 cells were plated and transfected with mTOR or Raptor siRNA as in 
A. After 72 hr, cells were treated with AICAR and/or PA as indicated for 45 min. The 
cells were then harvested and levels of phospho-TSC2 (P-TSC2), TSC2, phospho-
S6 kinase (P-S6K), S6K, phospho-4E-BP1 (P-4E-BP1), 4E-BP1 and actin were 
determined as in A. Relative levels of TSC2, S6K, 4E-BP1 phosphorylation were 
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normalized to total TSC2, total S6K, total 4E-BP1 respectively and quantified as in 
Fig 4.1A. C, MDA-MB-231 cells were plated as in Fig 4.1B, were treated with PLDi 
or AICAR for 1hr where indicated. The cells were then harvested and levels of P-
ULK1, ULK1 and actin were determined as in A. The data shown are representative 
of experiments repeated at least two times.  
 
4.3. Discussion 
          The level of nutrients and energy in cells is carefully monitored.  Two critical 
signaling nodes for nutrient and energy sensing are AMPK and mTORC1 with AMPK 
being activated in response to energy deprivation and mTOR being activated by 
nutritional sufficiency.  An emerging theme in cancer is that these signaling nodes are 
dysregulated with AMPK being suppressed and mTOR being activated during 
tumorigenesis (139).  One of the more common tumor suppressor genes is LKB1, which 
contributes to the suppression of AMPK when lost by mutation (140) – underscoring the 
importance of AMPK suppression in tumorigenesis.  In this report, we have provided 
evidence for reciprocal regulation of AMPK and mTOR involving PLD and its metabolite 
PA.  Suppression of PLD activity increased the phosphorylation of AMPK at the LKB1 site 
at Thr172 and ACC at the AMPK site at Ser79.  Exogenously supplied PA suppressed 
phosphorylation of AMPK and ACC in an mTORC1-dependent manner.   
 The suppression of AMPK in response to elevated PLD activity in cancer cells 
provides a positive feedback loop for sustaining elevated PLD and mTORC1 activity.  This 
keeps the TSC GAP activity suppressed, and thusly, Rheb remains GTP bound and 
capable of activating PLD1.  This is likely the case in cancer cells where PLD activity is 
commonly elevated (72).  However, the reverse could also be true and elevated AMPK 
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could suppress PLD activity, which would lead to less PA and an inactive mTOR – and 
as a consequence, prevent the suppression of AMPK.  In this case, there is a positive 
feedback loop that favors AMPK.  This is shown schematically in Fig. 4.5.  It is not clear 
at this point what it is that determines which loop will predominate – the one that favors 
AMPK or the one that favors PLD and mTOR.  However, this is an important point with 
implications for tumorigenesis and possible therapeutic options.  
                
Figure 4.5 Model for Reciprocal regulation of AMPK and PLD. Two scenarios are 
presented for the regulation of PLD by AMPK and the regulation of AMPK by PLD. 
A, AMPK is activated by the presence AMP and phosphorylation by LKB1. AMPK 
then phosphorylates TSC, which stimulates the GAP activity of TSC towards Rheb 
resulting in the hydrolysis of bound GTP to GDP and inactivation of Rheb. As a 
consequence, PLD does not get activated (56) and PA needed for stabilization of 
mTORC1(54)is not generated and mTORC1 is inactive. B, Rheb is GTP bound and 
promotes the production of PA by PLD and the stabilization of mTORC1. Active 
mTORC1 then causes suppression of AMPK in a manner that is likely dependent 
on S6 kinase in that rapamycin has been reported to activate AMPK (136) at 
concentrations that suppress S6 kinase (50). Other signals promoted by oncogenic 
stimuli contribute to the activation of this pathway such as mTORC2-Akt, which 
suppresses TSC (46) and Ras, which leads to PLD activation(141). It is also 
important to note that mTOR is an integrator on nutrient and growth factor signals 
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(25)– both of which are required for cell cycle progression and proliferation. mTOR 
requires amino acids (142), glucose (55), and possibly lipids (43) for activity. 
 
The regulation of mTOR by AMPK has two separate pathways – one that goes 
through phosphorylation of TSC2 and activation of the GAP activity towards Rheb 
(129,130).  However, AICAR can still suppress mTOR in TSC2-/- cells, which led to the 
discovery that AMPK can also suppress mTORC1 by direct phosphorylation of the 
mTORC1 substrate-recognizing subunit Raptor at Ser792 (143,144).  These findings 
indicate that the relationship between AMPK and mTOR is complex and that there may 
be multiple connections between the two signaling nodes that monitor nutrient and energy 
sufficiency.  It is not clear how PLD and mTOR suppresses AMPK, however it was 
reported previously that rapamycin can stimulate the phosphorylation of AMPK at the 
LKB1 site at Thr172 and ACC at the AMPK site at Ser79 (136).  This could be achieved 
at low nano-molar concentrations of rapamycin that suppress S6 kinase phosphorylation, 
but have no effect on the phosphorylation of 4E-BP1 (50,145) – suggesting a role for S6 
kinase. In contrast with cancer and other proliferating cells, AMPK stimulates glucose 
uptake when ATP levels are reduced (146).  Interestingly, it has been reported that AMPK 
activates PLD1 in muscle cells and that PLD activation is required for glucose uptake 
(147,148). This apparently occurs via direct phosphorylation of PLD1 by AMPK at Ser505 
and required ERK (147).  Whether the PA impacted on mTOR in these studies was not 
clear, but it has been reported that PLD can stimulate the mTOR-dependent expression 
of hypoxia-inducible factor1 and 2 (149,150), which promote glucose uptake and 
glycolysis (151).  These studies indicate that AMPK can both suppress and activate PLD1 
depending upon metabolic need. 
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A theme that has emerged in cancer is that it is critical to keep AMPK activity 
suppressed – as evidenced by the frequency of LKB1 mutations in cancer (77).  There 
are two means for AMPK to suppress mTOR – indirectly through phosphorylation of TSC 
(129,130), and directly through phosphorylation of Raptor (143,144).  It has been 
speculated that the most commonly dysregulated signals in human cancer are those that 
lead to elevated mTOR activity (7,152).  In this regard, it is significant that PLD activity is 
elevated in a wide variety of human cancers and cancer cell lines (71,72).  The finding 
here that PLD suppresses AMPK in an mTOR-dependent manner is consistent with a 
central role for PLD and its metabolite PA in signals involved in the regulation of nutrient 
and energy status.  PA occupies a central spot in membrane phospholipid biosynthesis 
and is therefore an ideal indicator of lipid sufficiency.  It could also indicate sufficient 
glucose and glutamine, which are key nutrients that are incorporated in to PA (153).  We 
have proposed that the PA requirement of mTOR evolved as a means to sense the 
presence of sufficient materials for membrane synthesis to complement the ability to 
sense amino acids (153,154).  Consistent with this hypothesis, the enzymes involved in 
the de novo synthesis of PA stimulate mTOR (155,156) – indicating that the PA 
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5.1. Introduction  
In the progression of a normal cell to a cancer cell, it is critical that there be a means to 
suppress default apoptotic programs that arguably are the first line of defense of cancer 
(157).   A critical signaling node that promotes the survival of cancer cells is mTOR – the 
mammalian/mechanistic target of rapamycin.  There are two mTOR complexes mTORC1 
and mTORC2 that have both been implicated in cancer cell survival signals.  It has been 
suggested that the signals that regulate mTOR are the most dysregulated signals in 
human cancer cells (7).  As a consequence, there has been substantial interest in mTOR 
as a therapeutic target for many human cancers (158,159).  Compounds that target 
mTOR have been employed in many clinical trials (160,161) – albeit without much 
success.  There are distinct classes of compounds that target mTOR: rapamycin and 
rapamycin analogs (rapalogs) and ATP-competitive inhibitors.  Rapamycin is a natural 
product that acts as an allosteric inhibitor that preferentially inhibits mTORC1 (162).  Both 
classes of inhibitors have inherent problems.  The ATP-competitive inhibitors are good in 
that they target both mTORC1 and mTORC2, which both contribute to survival; however, 
as with most ATP-competitive inhibitors, there is concern as to specificity for mTOR.  In 
contrast, rapamycin is highly specific for mTOR, but there are peculiar dosage issues 
associated with rapamycin (162). 
 Rapamycin inhibits different cells with different dose responses.  For example, 
phosphorylation of the mTORC1 substrate ribosomal subunit S6 kinase (S6K) in MCF7 
breast cancer cells is suppressed at 0.5 nM, but in MDA-MB-231 cells, you need 20 nM 
to suppress S6K (53).  This was due at least in part to the levels of phospholipase D 
(PLD) activity in the two cell lines.  PLD generates the metabolite phosphatidic acid (PA), 
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which interacts with mTOR in a manner that is competitive with rapamycin (53,54,58).  
Elevating PLD activity in MCF7 cells increased the dose of rapamycin to suppress 
phosphorylation of S6K, and similarly, reducing PLD activity in MDA-MB-231 cells 
reduced the dose needed to suppress S6K phosphorylation (53).  There is also a problem 
in that different doses of rapamycin are needed to inhibit the phosphorylation of different 
mTORC1 substrates.  The phosphorylation of S6K can be suppressed by low nano-molar 
levels; whereas phosphorylation of eukaryotic initiation factor 4E (eIF4E)-binding protein 
1 (4E-BP1) requires micro-molar doses (50).  This is an important issue because the 
apoptotic effects of rapamycin are due to suppressing phosphorylation of 4E-BP1 (50).  
The doses that can be achieved in the clinic do not approach the levels needed to inhibit 
4E-BP1 phosphorylation (163).  This is likely why rapalogs have been largely 
disappointing in clinical trials in that you cannot deliver doses of rapamycin that overcome 
the survival effect of mTORC1, which involves primarily the phosphorylation of 4E-BP1 
(50). 
 Another problem with rapamycin is that by suppressing S6K phosphorylation, it 
suppresses a negative feedback loop that keeps mTORC2 from phosphorylating and 
activating the survival kinase Akt, and as a consequence, rapamycin activates Akt 
(60,164).  Whereas, the catalytic ATP-competitive inhibitors suppress both mTORC1 and 
mTORC2 (160), under most conditions, rapamycin suppresses only mTORC1 (50).  Thus, 
activating mTORC2 by rapamycin treatment can lead to elevated Akt activity and 
suppress the apoptotic effects of rapamycin, which has been observed in pancreatic 




5.1.1 Purpose of the study in this chapter 
In order to take advantage of the high specificity of rapamycin for mTOR, there needs to 
be a means for making rapamycin effective at lower doses.  We reported previously that 
partial suppression of PLD activity in breast cancer cells resulted in the suppression of 
Akt at the mTORC2 site at Ser473 with 200 nM rapamycin (54).  Thus, suppression of 
PLD activity can improve the efficacy of rapamycin for both mTORC1 and mTORC2.  We 
very recently reported that PLD activity can be suppressed by activating AMP-dependent 
protein kinase (AMPK) with the AMP-mimetic compound AICAR (5-aminoimidazole-4-
carboxamide-1--4-ribofuranoside) (165).  We therefore investigated the effect of treating 
cancer cells with the combination of rapamycin and AICAR.  In this report we provide 
evidence that tolerable doses of rapamycin in combination with AICAR suppresses both 
4E-BP1 and Akt phosphorylation and induces apoptosis in cancer cells. 
 
5.2   Results 
5.2.1 AICAR Treatment Causes S-phase Cell Cycle Arrest  
We previously reported that cells arrested in S-phase of the cell cycle could be killed with 
rapamycin (166).  In this regard, it was of interest that activation of AMPK has been shown 
to cause S-phase cell cycle arrest (167).  AMPK can be activated by AICAR – a cell-
permeable nucleoside that is metabolically converted by adenosine kinase to 5-
aminoimidazole-4-carboxamide ribonucleoside monophosphate or ZMP, which mimics 
the allosteric effects of AMP and activates AMPK (135).  As shown in Fig. 5.1A, there was 
dramatic increase in cells with S-phase DNA content in both MDA-MB-231 and MCF7 
breast cancer cells treated with AICAR as determined by flow cytometry.  AICAR 
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suppressed proliferation of the MDA-MB-231 and MCF7 cells – indicating that the cells 
were actually arresting in S-phase and not just changing the duration of the cell cycle 
phases (Fig. 5.1B).  As shown in Fig. 5.1C, there were decreased levels of cyclin D1, 
phosphorylated Rb, and proliferating cell nuclear antigen (PCNA); and increased levels 
of cyclin A2 in both cell lines – consistent with the apparent S-phase cell cycle arrest.  
These data demonstrate that AICAR induces S-phase cell cycle arrest in these two breast 
cancer cell lines. Dose responses to AICAR were determined for cell cycle arrest (Fig. 
5.1D) and for the phosphorylation of AMPK and the AMPK substrate acetyl-CoA 




                             
Figure 5.1. AICAR treatment causes S-phase cell cycle arrest.  A, MDA-MB-231 and 
MCF-7 cells were plated at 30% confluence in 10-cm plates in DMEM containing 
10% serum. After 24 hr, the cells were treated with AICAR (0.5 mM) for 48 hr.  After 
48 h, the cells were harvested, fixed, stained with propidium iodide, and analyzed 
for cell cycle distribution by measuring DNA content/cell as described in Methods.  
The error bars represent the standard error of the mean for experiments repeated 
three times.  B, Cells were plated at 20% confluence in six-well plates in complete 
media containing 10% serum.  After 24 hr, AICAR (0.5mM) was added. Cells were 
harvested at indicated time points, stained using crystal violet, and quantified by 
light microscopy as described in Methods.  Error bars represent the standard error 
for an experiment repeated three times.  C, Cells were plated at 30% confluence in 
10-cm plates in complete media containing 10% serum for 24 h at which time they 
were treated with AICAR (0.5 mM) for 48 hr.  The cells were subsequently harvested 
and cell lysates were collected.  The indicated protein levels were determined by 
Western blot analysis.   The data shown are representative of experiments repeated 
at least two times. D, Cells were seeded as in B and treated with various 
concentrations of AICAR (0.25-2mM) for 48 hr, at which time the cells were 
harvested, stained using crystal violet, and quantified by light microscopy as 
described in Experimental Procedures. Error bars represent the standard error for 
an experiment repeated three times. E, Cells were seeded as in C and treated with 
various concentrations of AICAR (0.25-2mM) for 24 hr. Cells were harvested and 
the levels of phospho-AMPK, AMPK, phospho-acetyl-CoA carboxylase (P-ACC), 
ACC, and actin were determined by Western blot analysis. 
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5.2.2 AICAR Treatment Reduces the Concentration of Rapamycin 
to Induce Apoptosis 
 We next treated the MDA-MB-231 cells with rapamycin in combination with AICAR 
and looked for cleavage of the caspase 3 substrate poly-ADP-ribose polymerase (PARP) 
as an indicator of apoptosis.  As expected based on our previous study (166), arresting 
cells in S-phase with AICAR resulted in a sharp increase in the level of cleaved PARP 
when rapamycin was included (Fig. 5.2A).  What was not expected was that the dose 
required for induction of PARP cleavage was 1000-fold lower than that observed 
previously (50,53,166).  PARP cleavage was induced at 20 nM rapamycin; whereas 
previously, PARP cleavage required 20 M in MDA-MB-231 cells (Fig. 5.2B).  As shown 
in Fig. 5.2C, the combination of AICAR and 200 nM rapamycin led to increased levels of 
sub-G1 DNA content in the MDA-MB-231 and MCF7 cells – further supporting an 
apoptotic cell death.  This was also observed in Calu1 lung cancer cells (Fig. 5.2C).  
Importantly the apoptotic effect was not observed in the non-cancerous BJ-hTERT human 
fibroblast cell line.  We also performed a dose response curve for induction of PARP 
cleavage by rapamycin on MCF7 cells in the presence of AICAR and as shown in Fig. 
5.2D, PARP cleavage could be detected at 0.5 nM.  We previously reported that MCF7 
cells are much more sensitive to rapamycin than MDA-MB-231 cells and demonstrated 
that loss of viability in MCF7 cells was observed at 100 nM (53).  Thus, like the MDA-MB-
231 cells, the presence of AICAR reduced the effective dose of rapamycin needed to 
induce apoptosis.  Consistent with the lack of BJ-hTERT cells containing sub-genomic 
DNA (Fig. 5.2C), the combination of AICAR and 200 nM rapamycin also failed to induce 
PARP cleavage in these cells.  The data in Fig. 5.2 reveal that AICAR reduces the level 
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of rapamycin to induce apoptosis in cancer cells, while not inducing apoptosis in in the 




Figure 5.2 AICAR treatment reduces the concentration of rapamycin to induce 
apoptosis.  A, MDA-MB-231 cells were plated at 60% confluence in 60mm plates in 
DMEM containing 10% serum.  24 hr later the cells were treated with AICAR (2mM) 
and/or different doses of rapamycin as indicated for 24 hr.  The cells were then 
harvested and levels of cleaved PARP (Cl PARP) and actin were determined as in 
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Fig. 5.1C.  B, MDA-MB-231 cells were plated as in A.  24 hr later of plating, the cells 
were shifted to complete medium or medium lacking serum and treated with 
rapamycin at different doses for 24 hr.  The cells were then harvested and indicated 
protein levels were determined as in A.  C, MDA-MB-231, MCF-7, Calu-1 and BJ-
hTERT cells were plated at 40% confluence and treated with AICAR (0.5 mM) and/or 
rapamycin (200 nM) for 48 hr, after which these were collected and subjected to 
flow cytometric analysis.  Total subgenomic DNA is plotted as indicated.  Error 
bars represent S.D. values for at least two independent experiments.  D, MCF-7 
cells were plated in A.  The cells were treated with AICAR (2 mM) and/or varying 
doses of rapamycin as indicated for 24 hr.  The cells were then harvested and 
indicated protein levels were determined as in A.  E, BJ-hTERT cells were plated in 
A.  The cells were treated with AICAR (2 mM) and/or rapamycin (200 nM) for 24 hr. 
The cells were then harvested and indicated protein levels were determined as in 
A.  The data shown are representative of experiments repeated at least two times. 
 
5.2.3 Apoptotic Effects of AICAR and Rapamycin is Dependent on 
the Suppression of mTORC2 by Low Dose Rapamycin  
We next examined the efficacy of AICAR and rapamycin on mTORC1 and 
mTORC2 substrates in MDA-MB-231 cells.  As shown in Fig. 5.3A, AICAR treatment 
suppressed the phosphorylation of the mTORC1 substrates S6K and 4E-BP1.  However, 
AICAR stimulated phosphorylation of Akt at the mTORC2 site at Ser473 (Fig. 5.3A).  No 
PARP cleavage was detected with AICAR treatment alone (Fig. 5.3A).  Rapamycin (200 
nM) suppressed phosphorylation of S6K and weakly suppressed phosphorylation of 4E-
BP1 (Fig.5.3A), which is consistent with our previous report that micro-molar 
concentrations of rapamycin were needed to suppress phosphorylation of 4E-BP1 (50).  
Rapamycin, by itself, had no effect on the level of Akt phosphorylation or PARP cleavage 
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(Fig. 5.3A).  The most significant difference between the use of either rapamycin or AICAR 
by themselves vs rapamycin and AICAR in combination was that rapamycin completely 
suppressed Akt phosphorylation in the presence of AICAR and induced PARP cleavage 
(Fig. 5.3A).  Thus, AICAR also reduced the concentration of rapamycin needed to inhibit 
mTORC2 and suppress phosphorylation of Akt at Ser473.  The ability of rapamycin to 
suppress Akt phosphorylation is sufficient to induce PARP cleavage and apoptotic cell 
death in combination with AICAR, which efficiently suppressed S6K and 4E-BP1 
phosphorylation in the absence of rapamycin.    
 To establish that the suppression of Akt phosphorylation was due to rapamycin, 
we examined the effect of FK506 on S6K and Akt phosphorylation.  Rapamycin inhibits 
mTOR by combining with FK506-binding protein 12 (FK-BP12) and then binding to 
mTOR.  FK506 also binds FK-BP12 and competes with rapamycin, and thusly has been 
used to reverse the effects of rapamycin (54).  As shown in Fig. 5.3B, FK506 reversed 
the suppression of both S6K and Akt phosphorylation caused by treatment with both 
AICAR and 200 nM rapamycin.  This result demonstrates that rapamycin is responsible 
for the suppression of Akt phosphorylation at the mTORC2 site at Ser473.  
 It was previously reported that under some conditions, rapamycin induces 
dissociation of mTORC2 components mTOR and Rictor (54,168).  We therefore 
examined whether the combination of AICAR and lower dose rapamycin could dissociate 
mTOR from Rictor.  mTOR was immunoprecipitated from MDA-MB-231 cell lysates and 
then subjected to Western blot analysis for both Raptor (mTORC1) and Rictor (mTORC2).  
As shown in Fig. 5.3C, both AICAR and rapamycin, by themselves, cause dissociation of 
mTOR and Raptor.  However, significant dissociation of mTOR from Rictor occurred only 
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when rapamycin treatment was combined with AICAR (Fig. 5.3C).  We also examined the 
effect of AICAR treatment in MDA-MB-231 cells with knockdown of Rictor, and as shown 
in Fig. 5.3D, the knockdown of Rictor mimicked the effect of low dose rapamycin with 
regard to stimulating PARP cleavage and inhibiting Akt phosphorylation.  The key results 
of Fig. 5.3 are summarized in Fig. 5.3E.  These data further indicate that the key apoptotic 
effect of rapamycin in combination with AICAR is suppression of the mTORC2-catalyzed 
phosphorylation of Akt.  Collectively, the data in Fig. 5.3 indicate that the ability of AICAR 
and rapamycin to kill MDA-MB-231 cells is the result of AICAR suppressing mTORC1 and 








Figure 5.3. Apoptotic effects of AICAR and rapamycin is dependent on the 
suppression of mTORC2 by low dose rapamycin.  A, MDA-MB-231 cells were plated 
as in Fig 2A.  The cells were treated with AICAR (2 mM) and/or rapamycin (200 nM) 
for 24 hr. The cells were then harvested and levels of the indicated proteins or 
phospho-proteins were determined by Western blot analysis.  B, MDA-MB-231 cells 
were plated as in A and were treated with AICAR (2 mM), rapamycin (200 nM), FK-
506  (10μM)  for  24  h.  The  cells  were  then  harvested  and indicated protein levels were 
determined by Western blot analysis.  C, MDA-MB-231 cells were plated and treated 
with AICAR (2 mM) and/or rapamycin (200 nM) for 24 hr as in A. At this time, lysates 
were prepared and subjected to immunoprecipitation with anti-mTOR antibody 
overnight, and then the mTOR immunoprecipitate (IP:mTOR) was subjected, along 
with the lysates to Western blot analysis for Rictor or Raptor. Relative protein level 
of Rictor and Raptor were normalized to mTOR and quantified using LI-COR image 
studio software.  D, MDA-MB-231 cells were plated in 6 well plates at 30% 
confluence overnight.  The cells were then transfected with siRNAs for either 
scrambled control siRNA, or Rictor as indicated.  6 hr later, the cells were treated 
with fresh medium containing 10% serum for 48hr. AICAR (2 mM) was then added 
for an additional 24 hr where indicated. The cells were then harvested and the levels 
of indicated proteins were determined by Western blot analysis.  The data shown 
are representative of experiments repeated at least two times.  E, The key data for 
Fig. 5.3 are summarized in table form where the most critical numbers are in bold 
highlighting the key effects of the combination of AICAR and rapamycin. 
 
5.2.4 Effect of AICAR on Rapamycin efficacy is due to suppression 
of PLD activity 
          mTOR requires PA for stabilizing both mTORC1 and mTORC2 complexes (54) and 
for mTOR kinase activity (58).  Although there are several sources of PA, the most 
significant is likely PLD, which catalyzes the hydrolysis of phosphatidylcholine to PA and 
free choline (169).  Importantly, the highly conserved PA-binding domain on mTOR (154) 
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is at the same site where rapamycin binds (58); and rapamycin binds mTOR in a manner 
that is competitive with PA (53,54,58).  We reported previously that suppressing PA 
production by PLD reduced the level of rapamycin needed to inhibit both mTORC1 and 
mTORC2 (53,54).  We also reported very recently that activating AMPK with AICAR 
suppressed PLD activity (165) – suggesting the possibility that AICAR was reducing the 
dose of rapamycin needed to inhibit mTORC2 by suppressing PLD activity.  As reported 
previously (165), AICAR treatment of MDA-MB-231 cells reduced PLD activity (Fig. 5.4A).  
To determine whether the reduction in PLD activity was responsible for the increased 
sensitivity of rapamycin, we added PA to determine whether it would reverse the effect of 
AICAR on the dose of rapamycin needed to suppress Akt phosphorylation.  As shown in 
Fig. 5.4B, the ability of rapamycin to suppress the AICAR-induced phosphorylation of Akt 
at Ser473 was reversed by PA.  These data are consistent with the effect of AICAR on 
the rapamycin dose needed to suppress mTORC2 being due to suppressing PLD activity 
and the production of PA. The dissociation of mTOR from Rictor observed with AICAR 
and rapamycin in Figure 5.3C, was also reversed with PA. These data are consistent with 
the effect of AICAR on the rapamycin dose needed to suppress mTORC2 being due to 
suppressing PLD activity and the production of PA – leading to dissociation of mTOR and 
Rictor making free mTOR accessible to rapamycin 
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Figure 5.4 Effect of AICAR on rapamycin efficacy is due to suppression of PLD 
activity.  A, MDA-MB-231 cells were plated at 70% confluence in 60mm plates. 24 
hr later the cells were treated with AICAR (2 mM) for 45 min.  [3H]-myristic acid 
was also added for 4 hr to label lipids.  1-BtOH was added for 20 minutes, and the 
amount of the PLD-catalyzed transphosphatidylation product, phosphatidyl-
butanol,  was  determined  as  described  under  “Methods”.    Values  were  normalized  
to the levels of PLD activity in controls, which were given a value of 100%.  Error 
bars for PLD assays represent S.D. values for at least two independent 
experiments. The statistical significance (P value) was determined by a two-tailed, 
paired  Student’s t-test. *P ≤  0.01  compared  with  control.    B,  MDA-MB-231 cells 
were plated as in A and treated with AICAR (2 mM) and/or rapamycin (200 nM) for 
8  hr.  PA  (300μM)  was  added  where  indicated.    After  8h,  the  cells  were  harvested  
and the levels of the indicated proteins and phosphor-proteins were analyzed by 
Western blot analysis. For IP experiments, MDA-MB-231 cells were plated and 
treated  with  AICAR  (2  mM)  and/or  rapamycin  (200  nM)  for  24  hr.  PA  (300μM)  was  
added where indicated. At this time, lysates were prepared and subjected to 
immunoprecipitation with anti-mTOR antibody overnight, and then the 
immunoprecipitates were subjected to Western blot analysis for mTOR and 
Rictor. The data shown are representative of experiments repeated at least two 
times.    
5.3 DISCUSSION 
 We previously reported that arresting cells in S-phase renders most cancer cells 
sensitive to the apoptotic effects of rapamycin (166).  The ability of rapamycin to induce 
apoptosis was dependent on the ability to suppress the phosphorylation of the mTORC1 
substrate 4E-BP1, which required micro-molar doses of rapamycin (50).  A serious 
problem with rapamycin-based therapeutic strategies is that the micro-molar doses that 
are required for the apoptotic effect are toxic (163).  Another problem is that rapamycin 
suppresses a negative feedback suppression of Akt phosphorylation by mTORC2 leading 
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to elevated levels of phosphorylated Akt (60,164) that can overcome the apoptotic effect 
of rapamycin (62).  In this report, we describe a surprising finding that activating AMPK 
with AICAR not only promotes S-phase arrest, which sensitizes cells to the apoptotic 
effect of suppressing mTORC1, it also makes mTORC2 sensitive to nano-molar doses of 
rapamycin that are tolerated in the clinic. 
 The activation of AMPK by AICAR leads to the phosphorylation of tuberous 
sclerosis complex (TSC1/2), which acts as a GTPase activating protein for Rheb, and 
thusly turns off Rheb (170).  Rheb is required for the activity of both mTORC1 and PLD1 
(170).  Of interest, AICAR can suppress the phosphorylation of both S6K and 4E-BP1 
with equal efficiency.  This is not the case with rapamycin, which inhibits S6K 1000-fold 
lower doses than it inhibits 4E-BP1 (50).  Thus, AICAR can accomplish more than 
rapamycin accomplishes at conventional nano-molar doses.  However, there was an 
unanticipated benefit of combining AICAR with rapamycin – that being the suppression 
of PLD activity by AICAR, which sensitizes mTORC2 to rapamycin due to the reduced 
levels of PA generated (54).  This turned out to be critical because, like rapamycin, AICAR 
suppressed the negative feedback suppression of Akt (60,164), which lead to the 
phosphorylation and activation of Akt.  Activated Akt suppresses the apoptotic effect of 
suppressing mTORC1 (62).  Thus mechanistically, AICAR stimulates S-phase arrest, 
which sensitizes cells to suppression of mTORC1.  However, AICAR also suppresses 
PLD activity – making mTORC2 sensitive to rapamycin at clinically tolerated doses that 
can prevent the Akt phosphorylation stimulated by AICAR.  Thus, while the combination 
of AICAR and rapamycin might seem redundant – they both suppress mTORC1 – the 
ability of AICAR to suppress PLD activity, and as a consequence, make mTORC2 
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responsive to tolerated doses of rapamycin leads to suppression of mTORC2 as well as 
mTORC1.  Moreover, because AICAR suppresses 4E-BP1 phosphorylation more 
efficiently than rapamycin, the combination of AICAR and rapamycin leads to better 
suppression of this mTORC1 substrate that is the most critical for the survival effects of 
mTORC1 (50).   This is shown schematically in Fig. 5.5.   
                    
Figure 5.5 Model 
Model for differential doses of rapamycin needed to suppress mTORC2 in the 
presence and absence of AICAR.  In the upper model, PA levels are high, which 
strongly favors formation of the highly stable mTORC2 complex.  It was proposed 
that rapamycin inhibits mTORC2 only by binding newly synthesized mTOR before 
the complex forms.(168)  Since mTORC2 is so stable, mTOR complexed with Rictor 
(mTORC2) effectively never becomes available for binding to rapamycin.  However, 
as indicated in the lower model, when AICAR is present, PLD activity is suppressed 
and PA levels are reduced.  In this case, mTORC2 is destabilized and the 
equilibrium shifts towards free mTOR, which can bind rapamycin at low doses – 




A key motivation for investigating AICAR in combination with rapamycin was the 
observation that AICAR arrests cells in S-phase of the cell cycle (167) and that rapamycin 
kills cells arrested in S-phase (166).  That is effectively what was observed with the 
combination of AICAR and rapamycin.  As it turned out AICAR was able to efficiently 
suppress the phosphorylation of 4E-BP1, effectively negating the need for rapamycin.  
However, rapamycin, unlike AICAR arrests cells in G1 (166), indicating that activating 
AMPK does more than suppress mTORC1 in causing S-phase rather than G1 arrest.  And 
a critical factor for the apoptotic effect of mTORC1 suppression is arresting the cells in S-
phase (166).  Ironically, the critical contribution of rapamycin to the apoptotic effect of 
rapamycin in combination is the suppression of mTORC2-mediated activation of Akt. 
With regard to the importance of targeting mTORC2 and the phosphorylation of 
Akt, ATP-competitive catalytic mTOR kinase inhibitors have been developed that target 
both mTORC1 and mTORC2 and can suppress the phosphorylation of S6K, 4E-BP1 and 
Akt at Ser 473.(171)  Thus, in principle, the catalytic inhibitors are ideal therapeutic agents 
for treating cancers where the activation of Akt by suppression of mTORC1 is preventing 
apoptosis.  Consistent with this idea, we have found that torin1 kills BxPC3 pancreatic 
and that AZD8055 kills MCF7 breast cancer cells where Akt phosphorylation is elevated 
in response to rapamycin treatment.(50,172)  However, we have also observed that 
Torin1 arrests MDA-MB-231 cells under conditions where rapamycin induces apoptosis 
(our unpublished observations).  Thus, conditions exist where rapamycin is more toxic 
than a catalytic inhibitor.  In addition, several adverse effects have been noted for the 
catalytic inhibitors due to off-target effects of ATP analogues as well as potential 
additional effects of suppressing mTORC2.(173)  Therefore, the high specificity of 
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rapamycin for mTOR – even at the high micro-molar doses (50) – still has some 
advantages over the catalytic inhibitors.  The impact of AICAR on the dose of rapamycin 
needed reported here further enhances the relevance of rapamycin as a therapeutic anti-
cancer agent. 
          The findings reported here have potential clinically important implications. 
Activators of AMPK have been in use for many years to treat type II diabetes (78).  
Rapamycin and rapalogs have been widely employed in clinical trials (161).  Thus, 
targeting both AMPK and rapamycin has been widely employed in the clinic suggesting 
the feasibility using AMPK activators in combination with rapalogs.  This combination has 
previously been reported to be effective in suppressing the proliferation of acute 
lymphoblastic leukemia cells (174).  In addition, a phase I study with the rapalog 
temsirolimus in combination with metformin in advanced solid tumors has been performed 
with some positive responses (175).  Although no dramatic responses were reported, the 




























In chapter 3 we have concluded that K-Ras-driven cancer cells have been resistant to 
therapeutic intervention and K-Ras itself has been considered undruggable (176).  Thus, 
alternative strategies are needed for what may be as many of 30% of human cancers that 
are driven by K-Ras mutations(117).  The observation that K-Ras-driven cancer cells 
override a late G1 Gln-dependent cell cycle checkpoint and arrest in a part of the cell cycle 
where they are sensitive to cytotoxic drugs represents a potentially exploitable 
vulnerability of K-Ras-driven cancer cells.  The ability to target Gln utilization in 
combination with cell cycle phase specific cytotoxic drugs could provide a means for 
targeting a significant percentage of human cancers that have been resistant to 
therapeutic intervention.  
The most interesting and clinically significant future direction will be to confirm these 
studies in mouse model. KRAS mutant cells may fail to execute the nutrient-sensing 
checkpoint during glutamine starvation and this might have an impact on the later phases 
of cell cycle. Glutamine is an important nitrogen donor for nitrogenous bases for DNA 
synthesis and amino acids for protein synthesis. So when cells proceed to S phase, DNA 
replication may be slowed down due to shortage of nucleotides. Similarly, protein 
synthesis could be slowed down during G2 phase due to shortage of amino acids and 
this might lead to aberrant M phase. The prolonged S phase and G2/M phase might 
provide a broader time-window for the actions of cytotoxic drugs. Additional experiments 
could be carried out to check for these possibilities. Here are some examples of future 
experiments: a. Synchronizing cells (e.g., by flow cytometer) and grow them in glutamine 
deprived medium, monitor their cell cycle progression in a time course. This way, length 
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of each phase could be estimated. b. Examine Chk1 and Chk2 phosphorylation in the 
presence/absence of glutamine, with or without capecitabine. It will be also interesting to 
see whether pharmacological inhibitor of GLS (BEPTES) or genetic knockdown of GLS 
complement any results that stem from a blockade from glutaminolysis.  
  In chapter 4 our data indicate that the elevated PLD activity commonly observed 
in human cancer cells (71,72) contributes to the suppression of AMPK via activation of 
mTOR.  In this study we have provided evidence for a reciprocal regulation of PLD and 
mTOR by AMPK; and the regulation of AMPK by PLD and mTOR. Given that AMPK is 
an important mediator of energy homeostasis, it is not surprising that AMPK regulates the 
level of PA – a metabolite at the center of membrane lipid biosynthesis and a critical factor 
for mTOR activity. In future study it will be interesting to show Rheb-independent 
activation and lysosomal translocation of mTORC1 is dependent on PLD activity. 
In chapter 5 the study did reveal that the combination of AMPK activation and 
rapalog is well tolerated.  It will be important to establish whether there is a subset of 
cancers with specific genetic alterations that are especially sensitive to this two-pronged 
therapeutic approach. The clinically significant future direction will be to confirm these 
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